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Background: Abdominal adiposity and fat mass increase with aging, and as does insulin 
resistance which is frequently associated with hyperleptinemia and leptin resistance. 
Serum leptin may predict risk of metabolic syndrome and mortality among older adults. 
Objectives: The objectives of the present study were to evaluate the relationship of 
serum leptin with risk of metabolic syndrome and mortality and to examine these 
associations in relation to the measures of body adiposity and proinflammatory cytokines. 
The influence of leptin receptor (I/D) gene polymorphism on diabetes as a contributing 
cause of mortality was also examined. Gender specific serum leptin cut off values as a 
biomarker for the risk of metabolic syndrome were determined. 
Design: The Health, Aging and Body Composition (HABC) study is a prospective cohort 
of 3,075 older adults aged 70 to 79 years. Body composition, demographic information, 
biochemical variables including, markers of systemic inflammation, and genetic variation 
were assessed in detail. 
  
Results: Women in quintile 2, 3, 4 and 5 of serum leptin were at significantly lower risk 
for metabolic syndrome as compared to those in quintile 1 after controlling for 
confounders. Serum leptin was independently associated with risk of metabolic syndrome 
after sequentially adjusting for demographic variables (p<0.0001), fat depots (p=.0024), 
and proinflammatory cytokines (p=.0098) in women. Among men, the association 
between serum leptin and risk of metabolic syndrome was explained by body adiposity. 
Women in quartile 2 and 3 of serum leptin were at lower risk than women in quintile 1 
for all-cause mortality and mortality from cardiovascular disease independent of body fat 
and proinflammatory cytokines. Additionally, elevated level of serum leptin was 
associated with increased risk for diabetes as a contributing cause of mortality for both 
genders after sequentially adjusting for potential confounders, body fat and 
proinflammatory cytokines. Significant interaction was found between leptin receptor 
genotype and total percent fat (p=0.008) in association with diabetes as a contributing 
cause of mortality among women. The cut off serum leptin level that suggests the 
possible risk of metabolic syndrome was determined to be 6.45 ng/ml with 60% 
sensitivity and 63% specificity among men and 18.25 ng/ml with 55% sensitivity and 
62% specificity among women.  
Conclusion: Elevated levels of serum leptin may be associated with increased risk of 
metabolic syndrome and risk of diabetes as a contributing cause of mortality among older 
women. However, intermediary levels of serum leptin may lower the risk of all-cause 
mortality and mortality from CVD, suggesting a paradoxical association of serum leptin 
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Chapter 1: Introduction 
 
Based on the National Cholesterol Education Program, Adult Treatment Panel III 
definition, slightly more than one-third of the adults in United States have been characterized as 
having metabolic syndrome (1). The prevalence of metabolic syndrome increased from 20.3% 
and 15.6% among males and females, respectively, under 40 years of age to 51.5% and 54.4% for 
males and females, respectively, 60 years of age and older (1) (Figures 1.1). This is an important 
issue because the population of older adults is expanding and as this trend which is projected to 
continue (Figures 1.2) (3 and 5), will concurrently increase the prevalence of age-associated 
diseases (2 and 4). 





















































Figure 1.2 Projected U.S. Populations Aged 65 and Older: 2010 to 2050 (5) 
 
In the past decade, identification of the hormone leptin in adipose tissue established the 
latter as a metabolically active organ that plays a crucial role in food intake and energy 
expenditure (6). Recently, elevated levels of serum leptin in obese state have been shown to result 
in the development of leptin resistance (7 and 8). This has drawn considerable  attention to the 
role of hyperleptinemia on the risk of metabolic diseases and survival. There is a concomitant 
increase in serum leptin levels and in the expression of suppressor of cytokine signaling 3 
(SOCS3) (11 and 12) along with the amplification in fat mass and insulin resistance (9 and 10) 
among older adults, suggesting that aging is associated with leptin resistance, a mediator of 
metabolic disorders (9 and10). 
Serum leptin reflects the amount of energy stored in body. Elevated levels of serum leptin 




linked to impaired insulin action (14) and insulin resistance (15). Leptin resistance in pancreatic ß 
- cells contributes to dysregulation of adipoinsular axis leading to hyperinsulinemia and type 2 
diabetes (16). Leptin is not only implicated in the lipotoxicity of peripheral tissues but, has also 
been shown to play a critical role in the inflammatory response because of structural and 
functional similarities with the IL-6 family of cytokines (7). A parallel increase in 
proinflammatory cytokines and serum levels of leptin has been associated with aging, dementia, 
atherosclerosis, metabolic syndrome (7 and 13) and mortality.  
Several previous epidemiological studies have linked serum leptin levels to indicators of 
health and showed that elevated levels of serum leptin increase the risk of metabolic diseases 
cross-sectionally (17, 18, and 19). It would be interesting to see if serum leptin is prospectively 
associated with the risk of metabolic syndrome among older adults. Pro-inflammatory cytokines 
are related to serum leptin levels and have been implicated in the pathogenesis of several chronic 
diseases and mortality, but the contribution of pro-inflammatory molecules to the association of 
serum leptin with metabolic syndrome and mortality has not been explored in previous studies. 
Although several studies have shown positive association between hyperleptinemia and risk of 
cardiovascular disease (17, 18, and 19), some have also reported protective effect of leptin in 
heart failure (61 and 62).  Studying the association of serum leptin with metabolic syndrome and 
mortality in context of body adiposity and inflammatory factors will provide a complete picture 
of the role of serum leptin on the risk of metabolic syndrome and mortality. 
The objectives of the present study are: 
1.  To determine the prospective association of serum leptin with metabolic syndrome 
and to examine whether these associations are influenced by: 
§ Measures of body adiposity such as, BMI, total percent fat, visceral fat, and subcutaneous 
fat  
§ Markers of inflammation such as, C-reactive protein, plasminogen activator inhibitor -1, 





2. To examine the association between serum leptin with all-cause mortality, 
mortality from cardiovascular disease and from diabetes as a contributing cause of 
mortality and by leptin receptor (I/D) genotype. These associations were examined by:  
§ Total percent fat  
§ Markers of inflammation such as, C-reactive protein, plasminogen activator inhibitor -1, 
tumor necrosis factor – a,  and interleukin - 6  
 
3. To determine the gender specific cut off point of serum leptin as a biomarker of 








Chapter 2: Literature Review 
 
A. Leptin and Metabolic Health 
 
Leptin has been associated with inflammation, obesity, hypertension and insulin 
sensitivity, all of which are believed to increase risk of several chronic diseases and mortality 
(29, 33, 36, 51 and 60). Because of its association with several components of metabolic 
diseases, circulating levels of serum leptin may be a potential predictor of metabolic syndrome 
and play an important role in survival.  
 
What is Leptin?  
 
Leptin is a 16-kDa adipocyte-derived protein hormone. It is comprised of four a-helices 
and two short ß-strands that contain an intra-chain disulfide bond responsible for its biological 
activity (20). Its structure suggests that it belongs to the cytokine family (7). White adipose is the 
principle source of circulating leptin. Lesser amounts are also synthesized in and secreted from 
the hypothalamus, pituitary, skeletal muscle, and bone, arterial endothelium, intestines, fetus, 
testes and placenta (20).  
Leptin signaling occurs when leptin attaches to its receptor. The leptin receptor (Ob-R) is 
a member of the cytokine receptor family and is encoded by the db gene (20). While there are 
several forms of Ob-R (20 and 21), ObRb is main mediator of leptin signaling in several tissues 
(20, 12 and 11). The receptors for leptin are present in many areas of the brain, including the 
hypothalamus, cerebellum, cortex, hippocampus, thalamus, and brain capillary endothelium (21). 
These are also expressed in peripheral tissues, including the lung, kidney, liver, pancreas, 






Functions of Leptin 
 
In hypothalamus, leptin interacts with the receptors on neuropeptide Y/ Agouti related 
peptide (NPY/AgRP) neurons to suppress these orexigenic peptides (7, 22, 23, and 24) and 
trigger anorexigenic (POMC/CART) peptides (7, 23, and 24). This results in sympathetic 
stimulation and food intake inhibition (26). However, during the low levels of circulating 
leptin the orexigenic peptides are stimulated, anorexigenic peptides are inhibited (26) leading 
to reduced sympathetic activity, reduced energy expenditure and stimulated feeding behaviour 
(26). In liver and muscle, leptin activates 5’ - Adenosine Mono Phosphate – activated Protein 
Kinase (AMPK). Activated AMPK decreases glucose regulated transcription, protein 
synthesis, cholesterol synthesis, triglyceride synthesis and increases ß –oxidation, glucose 
transport and glycolysis (74). Thus, the net action of leptin is to inhibit appetite, stimulate 
thermogenesis, enhance fatty acid oxidation, decrease glucose, and reduce body weight and fat 
(22). 
 
Mechanism of Action of Leptin  
 
Binding of leptin to Ob-Rb receptor provides intracellular signaling by activating 
Janus kinase–signal transducers and activators of transcription (JAK–STAT) pathway via 
STAT 3 proteins in the hypothalamus. Leptin receptor signaling through the JAK2-STAT3 
pathway is under the negative feedback control of suppressor of cytokine signaling 3 (SOCS3) 
proteins (22, 12, and 11). Binding of Leptin to its receptor induces SOCS3 in NPY and pro-
opiomelanocortin (POMC) neurons and over expression of SOCS3 reduces JAK-STAT 




(12 and 11) along with the increase in fat mass and abdominal adiposity during aging, as well 
as an increase in insulin resistance, suggesting that it could be a mediator of leptin resistance 
in aging individuals (37 and 57).  
 
Figure 2.1 Mechanism of Leptin Signaling (25) 
 
Leptin Receptor Polymorphism 
 
Genetic, environmental and life style factors are believed to influence the changes in 
body composition and risk of metabolic diseases. The leptin receptor gene is a candidate gene 
for obesity and is located close to the marker (DIS198) of insulin secretion on human 
chromosome (11). Expression of the leptin receptor gene in pancreatic beta-cells is believed to 
play an important role in leptin-induced inhibition of insulin secretion (65), resulting in 
hyperinsulinemia (65 and 66). Both leptin receptor and SOCS3 are expressed in peripheral 
Adipose Tissue 
Serum Leptin 
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tissues such as liver, pancreas, and kidney and increased levels of SOCS3 in these peripheral 
tissues may result in decreased leptin receptor signaling and leptin resistance (12 and 28).  
Recently, pentanucleotide insertion in the 3’-untranslated region of the leptin receptor gene 
has been shown to be associated with weight change (70) and serum insulin levels (67). 
Similarly, Lakka et al., in a prospective case-control study on middle-aged men, reported 
lower serum insulin levels and type 2 diabetes (T2D) risk among participants homozygous or 
heterozygous for insertion allele (I/I or I/D) as compared to those who were homozygous for 
deletion allele (D/D) (68 and 69). Furthermore, in a study on overweight postmenopausal 
women, leptin receptor gene polymorphisms were shown to be associated with abdominal fat 
(71), while variations in DNA sequence in the leptin receptor gene was suggested to play a 
role in body fat distribution (71). Thus, the association of leptin receptor (I/D) polymorphism 





Serum leptin has been shown to play a critical role in inflammatory activity (7) and has 
been linked to serum levels of markers of systemic inflammation such as C reactive protein 
(CRP), tumor necrosis factor – a (TNF- a), and interleukin 6 (IL6) (33, 34, and 35). In vitro, 
leptin has been shown to play a critical role in the inflammatory response (7) by augmenting 
the proliferation of leukocytes and controlling the humoral inflammatory responses via its 
effect on T-cells, endothelial cells, monocytes, and neutrophils (35). Gainsford et al., 
demonstrated that leptin is associated with increased production of pro-inflammatory 
cytokines such as TNF-a, IL-6 and IL-12 in monocytes and macrophages (75).  Similarly, 
several previous studies have shown that there is a concomitant increase in the serum levels of 




dementia and atherosclerosis (33, 35, 38, 39, and 51). Furthermore, increased levels of serum 
leptin (49), IL-6 (30), TNF- a, (31), elevated acute phase proteins (32), and increased levels of 
markers of endothelial cell dysfunction and activation (29) have all been linked to human 




Both adipokines and pro-inflammatory cytokines have been implicated in the etiology 
of metabolic syndrome (40 and 41). Leptin directly inhibits insulin secretion from pancreatic 
ß- cells (46). Elevated serum leptin levels are associated with fasting insulin, insulin resistance 
(HOMA-IR), and total cholesterol (40, 42, 43, 45, 47 and 136). Leptin mediated dysregulation 
of body fat distribution has a cause-effect relationship between age-associated increase in 
visceral fat and the decrease in hepatic insulin action (44), which are major determinants of the 
metabolic syndrome (137 and 144). Recombinant human leptin given by subcutaneous 
injection (0.01 mg/kg and 0.03 mg/kg twice daily) for successive 3 month periods has been 
shown to lower visceral fat, improve dyslipidemia and insulin sensitivity in patients with HIV-
associated lipoatrophy (142). In a crossectional study on healthy male subjects, Francisco et al. 
found that plasma leptin concentration was associated with the metabolic disturbances that 
constitute the metabolic syndrome, including over all and central obesity, elevated blood 
pressure, insulin resistance, hyperinsulinemia, high plasma triglycerides, and elevated serum 
uric acid (40). Ruige JB et al, in a large population study, confirmed a positive correlation 
between serum leptin and basal insulin and found relationships between serum leptin and 
triacylglycerols independent of gender and BMI (48). Similarly among postmenopausal 
women, Lichnovska et al. showed the positive association between serum leptin and insulin 
resistance independent of increase in BMI (17). Furthermore, Buettener et al. proposed that 




new component of the metabolic syndrome among subjects aged 49.4 ±0.3. They also 
suggested that subjects with relative hyperleptinemia develop the metabolic syndrome at an 




Serum leptin has been implicated in development of several age-associated chronic 
diseases such as atherosclerosis, insulin resistance, diabetes, and osteoporosis (17, 36, 52, 53, 
and 54). Leptin also plays a critical role in energy intake (55 and 56), inflammatory response 
(55) and is strongly correlated with body fat (17, 57, 58, and 59), all of which are linked to 
mortality (34). These correlations suggest a potential role of serum leptin in mortality. Several 
previous studies have implied that serum leptin is associated with all-cause mortality and CVD 
mortality (60 and 61). In Framingham Heart Study, Lieb et al. found a U-shaped association 
between serum leptin and all-cause mortality with elevated risk of death at both low and high 
levels of leptin (60). Additionally, hypoleptinemia has been shown to elevate the risk of cancer 
mortality (63), while hyperleptinemia increased the risk of T2D mortality (62). Similarly in a 
longitudinal study on middle age women, moderately elevated serum leptin was inversely 
associated with CVD mortality after adjusting for adiposity (64). Furthermore in a 
PROspective Study of Pravastatin in the Elderly at Risk trial (PROSPER), Welsh et.al. found 
an independent association between T2D risk and serum leptin after adjusting for potential 
confounders and BMI (62).  
 
B. Rationale  
Although, leptin was shown to be associated with the increased production of pro-




aging (37 and 39) , atherogenic activity (31 and 54), metabolic syndrome (40 and 50), and 
mortality (34), the association of serum leptin with metabolic syndrome and mortality 
independently of pro-inflammatory compounds has not been explored in the previous studies. 
Therefore, the current study examines the associations of serum leptin with metabolic 
syndrome, all-cause mortality, and mortality from CVD, as well as with diabetes as a 
contributing cause of death before and after adjusting for inflammatory factors and body 
adiposity among functionally well older adults. While leptin receptor gene polymorphism has 
been shown to be associated with serum insulin levels (67 and 69) and body adiposity (70 and 
71), none of the previous studies explored the multiplicative effect of leptin gene 
polymorphism and body adiposity on the risk of T2D. Because the leptin receptor has 
structural and functional similarity with other members of cytokine family such as IL-6 (7), 
the influence of the proinflammatory cytokines on the association of leptin receptor genotype 





Chapter 3: Methods 
 
A. The Health, Aging and Body Composition (Health ABC) Study Design 
The Health, Aging and Body Composition (Health ABC) study is a longitudinal 
cohort study of community dwelling, well functioning older adults initiated by the Laboratory 
of Epidemiology, Demography, and Biometry of the National Institute on Aging (NIA) of the 
National Institutes of Health (NIH). The objective of Health ABC is to investigate the 
associations between changes in body composition, incident functional limitation, behavioral 
factors, and weight-related health conditions.  
At baseline, between April 1997 and June 1998, 3075 participants aged 70-79 years 
were recruited in the study from a random sample of white residents receiving Medicare 
benefits and all age-eligible black residents of Pittsburgh, Pennsylvania and Memphis, 
Tennessee. The sample included 48% men and 52% women at baseline. Of the men, 33% 
were African Americans and 67% Caucasians, while among women, 46% were African 
Americans and 54% Caucasians. Subjects were considered eligible to participate in the study 
if they reported no difficulty walking a quarter of a mile, climbing 10 steps without resting, or 
performing basic activities of daily living, were free of life-threatening illness, and planned to 
remain in the geographic area for at least 3 years. Those who reported active treatment for 
cancer or participation in diet or exercise intervention were excluded from the study. 
Participants gave written informed consent, and protocols were approved by the Institutional 
Review Boards at the Universities involved in the two study sites.  A home interview was 
administered to collect information on demographic, socioeconomic factors, and health 
behaviors. A clinic visit was conducted at baseline to collect blood samples, gather 




and physical function.   Subsequently, follow-up clinical examinations were conducted 
annually, and telephone interviews semi-annually. 
B. Data Preparation 
Data obtained at baseline and through year 10 were analyzed for this study. The 
Health ABC study consists of extensive information on anthropometric, biochemical, clinical, 
demographic and genetic variables. Data on specific prevalent diseases at baseline, indicators 
of the incidence of these same diseases during follow-up, and mortality are also available. 
Reliability and reproducibility of anthropometric, biochemical, dietary and clinical data 
collection methods were evaluated by Health ABC study. The Health ABC data set is sorted 
by a unique enrollment identification number (HABCID) that is assigned to each participant. 
In our study, we used the HABCID to extract the variables of interest from each data set and 
merge the files. In the final data set, main variables of interest were recoded to either reduce 
the number of groups within categorical variables, or to exclude missing values from the 
analysis. The cytokines, included in the study, were not normally distributed and were log-
transformed. All the analyses were performed using SAS (version 9.1; SAS Institute Inc., 
Cary, NC). 
C. Statistical Methods  
Analysis of Baseline Characteristics  
Because both low and high levels of serum leptin have been shown to be associated 
with metabolic disorders (47 and 48), participants were grouped either in quintiles or quartiles 
of serum leptin depending upon the sample size of the analysis. Grouping observations 
according to serum leptin quintiles and getting separate parameter estimates for each level not 
only mitigated the lack of linearity between leptin and logit of response variable but, also 




leptin levels have been shown to vary by gender (72), all the analyses were performed 
separately between men and women. Baseline characteristics of the participants in quintile 2, 
3, 4 and 5 were compared with those in quintile 1 by Dunett’s test for continuous variables and 
chi-square test for categorical variables. Potential confounders included in the study were age, 
gender, race, study site, education, smoking status, alcohol use, physical activity, calorie 
intake, hormonal replacement therapy, fasting insulin, number of hours fasted before blood 
was drawn, markers of systemic inflammation (CRP, TNF- a, IL-6 and PAI-1) and body 
adiposity. 
 
Multivariate Logistic Regression Model 
Logistic regression allows prediction of discrete variables by a combination of 
continuous and discrete predictors. It is frequently used by researchers because it is not based 
on any assumption regarding linear relationship between response and predictor variable, 
normal distribution of response variables or error terms, and homogeneity of variance for 
response variable. However, it does assume a linear relationship among the explanatory 
variable and the logit of the response variable. When the assumption of linearity in the logits is 
violated, then logistic regression underestimates the degree of relationship between the 
explanatory and the response variable and thus, lacks power. All the explanatory variables 
were checked for multicolinearity. 
Multivariate logistic regression models were constructed to determine the association 
between baseline serum leptin quintiles and risk of developing metabolic syndrome at year 6 
after adjusting for potential confounders. Trend analyses were performed to explore the linear 






Cox Proportional Hazard Regression Model 
Cox proportional hazard regression model is used for analysis of time until an event 
or time between events. One or more predictor variables are used to predict an event (response) 
variable. The event variable is analyzed in relation to a time variable and a hazard or survival 
rate is the main outcome. A hazard rate at a specified time is the probability of an event 
occurring in that time period, given survival through all prior time intervals. A hazard ratio is 
the estimate of the ratio of the hazard rate in one group to the hazard rate in another group. For 
continuous variables, hazard ratio is the ratio of the hazard rate given one unit increase in the 
covariate to the hazard rate without such an increase. The proportional hazard model is not 
based on any assumptions concerning the nature or shape of the underlying survival 
distribution. However, its main assumption is the proportionality assumption which specifies 
that the ratio of the estimated hazards over time will be constant. To check the proportionality 
assumption, the association between covariates and the survival time variable was investigated 
by computing and plotting the estimates of the survival distribution function. Test of equality 
across strata was also considered to select the predictors for the final model.  
Cox proportional hazard regression analysis was utilized to assess the relationship 
between serum leptin and all-cause mortality, and mortality from cardiovascular disease. The 
same statistical method was applied to examine the association between leptin, leptin receptor 
gene polymorphism and diabetes as a contributing cause of death. Trend analyses were 
performed to explore the linear relationship between serum leptin and mortality after 
adjustment for potential confounders.    
 
Receiver Operating Characteristic (ROC) Curves 
ROC curves are useful for assessing the accuracy of a diagnostic test in 




performance of a test are the sensitivity and specificity. Sensitivity, also called the true 
positive rate (TPR), is the probability of diagnosing the presence of disease when it is actually 
present. Specificity, also called true negative rate (TNR) is the probability of identifying the 
absence of disease when it is not present. The ROC curve is a graphical plot of the sensitivity 
(along the vertical axis) against 1 minus the specificity (along the horizontal axis).The ideal 
sensitivity and specificity is one. A diagonal line on the graph from the lower left hand corner 
to the upper right hand corner reflects a test with no discriminating power. The closer the 
graph gets to the upper left hand corner, the better the test is at discriminating between disease 
cases and noncases. ROC curve enables us to select a specific value of an indicator variable to 
use as a threshold that provides a desired trade off in sensitivity and specificity. A lower 
threshold cut-off results in a higher sensitivity and lower specificity. In other words, the 
number of false-negatives decreases and the number of false-positives increases. Inversely, a 
higher threshold cut-off value results in a lower sensitivity and higher specificity. 
The ROC curve was used to determine optimal cut off point of serum leptin 
concentration for diagnosis of metabolic syndrome cross-sectionally. The gold standard for the 
ROC curve was based on the presence of the metabolic syndrome at year 6. Multivariate 
logistic regression analysis was used to assess the relative risks of developing metabolic 
syndrome at year 6 among persons below the cut off value as compared to those above the cut 







Chapter 4: Hyperleptinemia, Adiposity and Risk of 
Metabolic Syndrome in Older Adults 
 
Abstract 
Background: Total fat mass and particularly abdominal adiposity increase with 
aging, and as does insulin resistance which is frequently associated with leptin resistance and 
high leptin levels.  
Objectives: This study investigates the prospective association between serum 
leptin and the risk of metabolic syndrome and examines this association in relation to 
measures of body adiposity and proinflammatory cytokines. 
Design:  The Health, Aging and Body Composition (HABC) study is a prospective 
cohort of 3,075 older adults aged 70 to 79 years. Partcipants’ body mass index, total percent 
fat, visceral fat, and subcutaneous fat were assessed. Plasminogen activator inhibitor I, 
interleukin-6, C-reactive protein, and tumor necrosis factor-a were measured by enzyme 
linked immunosorbant assay (ELISA).  
Results: Serum leptin quintile 2 (p=.008), 3 (p=.009), 4 (p=.0002), and 5 (p<.0001) 
were found to be significantly associa ted with the risk of  metabolic syndrome as compared to 
quintile 1 after adjusting for potential confounders (age, gender, race, study site, education, 
smoking status, alcohol use, physical activity, and calorie intake) among women. Serum leptin 
remained independently associated with the risk of metabolic syndrome after adjusting for fat 
depots (p=.0024) and proinflammatory cytokines (p=.0098), in women. Among men, 





Conclusion: Among older adult women, elevated concentrations of serum leptin 




Leptin is an adipocyte derived polypeptide hormone that influences feeding 
behavior through its direct effect on the hypothalamus (6). Serum levels of leptin reflect the 
amount of energy stored in adipose tissues (7). Previous studies have reported that serum 
leptin levels decrease with aging and that older adults have lower levels of circulating leptin as 
compared to younger adults (9, 76, and 38). However, recent studies refuted these previous 
findings and demonstrated that aging is accompanied by an increase in serum leptin levels (36 
and 37). Leptin plays a critical role in the inflammatory response (35), apparently due to the 
structural and functional similarities of leptin and its receptor with the IL-6 family of cytokines 
(7). A concomitant increase in TNF- a and serum leptin with aging has been associated with 
obesity and atherosclerosis (7 and 38).Both adipokines and pro-inflammatory cytokines are 
implicated in the etiology of insulin resistance (40) and metabolic syndrome (40 and 41). 
Leptin directly inhibits insulin secretion from pancreatic ß- cells (46) and elevated serum 
leptin levels are shown to be associated with fasting insulin, insulin resistance (HOMA-IR), 
and total cholesterol (40, 42, 43, 45, 136 and 137), that are the core metabolic disturbances of 
the metabolic syndrome. It has been also demonstrated in elegant experiments on rodent 
models that failure of leptin to “cross talk” with other fat depots to regulate fat distribution has 
a cause-effect relationship between the age-related increase in visceral fat and decrease in 
hepatic insulin action (44), major determinants of the metabolic syndrome (137 and 144). 
Although the proinflammatory cytokines are associated with serum leptin and are 




leptin with metabolic syndrome was not explored in light of proinflammatory cytokines and 
body fat depots among older adults. 
The primary objective of this study is to examine the association between serum 
leptin and the development of metabolic syndrome over a 6-year follow-up among a cohort of 
older adults and examine whether such an association may be independent of markers of 
inflammation and body fat. 
 
Subjects and Methods  
Study Design 
The Health, Aging and Body Composition (Health ABC) study is a longitudinal 
cohort study of 3,075 community dwelling, well functioning white and black men and women 
aged 70 to 79 years at the commencement of the study. Participants were recruited for the 
study from a random sample of white residents receiving Medicare benefits and all age-
eligible black residents of Pittsburgh, Pennsylvania, and Memphis, Tennessee. Subjects were 
considered eligible to participate in the study if they reported no difficulty walking a quarter of 
a mile, climbing 10 steps without resting, or performing basic activities of daily living, were 
free of life-threatening illness, and planned to remain in the area for at least 3 years. Those 
who reported active treatment for cancer or participation in diet or exercise intervention were 
excluded from the study. Participants gave written informed consent, and protocols were 
approved by the Institutional Review Boards at the two study sites.  A home interview was 
administered to collect information on demographic, socioeconomic factors, and health 
behaviors. A clinic visit at baseline was conducted for examination of biological variables, 
body composition, weight-related health conditions, and physical function between April 1997 
and June 1998.  Thereafter, follow-up clinical examinations have been conducted annually, 






In the present study data from baseline and year 6 of the Health ABC study were 
used. The exclusion criteria were having prevalent metabolic syndrome at baseline (n = 773); 
having an energy intake of less than 800 kcal/day or more than 4,000 kcal/day among men (n 
= 88) and an energy intake of less than 500 kcal/day or more than 3,500 kcal/day (n = 64) 
among women; and if the participants had missing or implausible values for the metabolic 




Participants underwent venipuncture at baseline visit after an overnight fast, and 
serum samples were frozen at -70°C. Plasma glucose levels were measured using an 
automated glucose oxidase reaction (YSI 2300 Glucose Analyzer; Yellow Springs 
Instruments, Yellow Springs, OH). Triglyceride (TG) and high-density lipoprotein cholesterol 
(HDL-C) levels were measured using a chemical analyzer (Vitros 950; Johnson & Johnson, 
Raritan, NJ). Both interleukin-6 (IL-6) and tumor necrosis factor- a (TNF- a) levels were 
measured in duplicate using an ultrasensitive enzyme-linked immunosorbent assay (R&D 
Systems, Minneapolis, MN). The limit of detection was 0.10 pg/ml for IL-6 and 0.18 pg/ml for 
TNF- a. The level of plasminogen activator inhibitor-1 (PAI-1) was measured in citrated 
plasma samples using a 2-site enzyme-linked immunosorbent assay according to previously 
published methods (91). The assay had coefficient of variation of 3.5%. Serum levels of C-
reactive protein (CRP) were also measured in duplicate by enzyme-linked immunosorbent 
assay based on purified protein and polyclonal anti-CRP antibodies (Calbiochem, San Diego, 
California) with a coefficient of variation (CV) of 8.0%. Serum concentrations of leptin were 
measured in duplicate by means of radioimmunoassay (Linco Research Inc, St Charles, Mo). 




Intraassay CVs ranged from 3.7% to 7.5%, and interassay CVs ranged from 3.2% to 8.9%. 
The assay is highly specific for human leptin and shows minimal reactivity with mouse or rat 
leptin. 
 
Anthropometric and Clinical Variables 
Weight was measured using a standard balance beam scale in kilograms. Height was 
measured twice using a Harpenden stadiometer (Holtain Ltd., Crosswell, U.K.) in centimeters 
and the average of the two measurements was used. BMI [weight (kg)/height (m2)] was 
calculated. At baseline, and year 6 of the Health ABC study, axial computerized tomography 
(CT) scanning of abdomen of the participants was performed.  Abdominal visceral and 
subcutaneous fat were quantified from scans, performed on a General Electric 9800 Advantage 
(Milwaukee, WI) in Pittsburgh and a Siemens Somatom Plus (Iselin, NJ) and Picker PQ2000S 
(Cleveland, OH) in Memphis.  CT scans were analyzed by the CT Scan Reading Center 
(CTSRC) of the University of Colorado Health Sciences Center according to a standardized 
protocol (77). Dual energy x-ray absorptiometry (DXA) (Hologic QDR 4500A, software 
version 8.21, Hologic, Waltham, MA) was used to assess the total fat mass and total 
percentage of body fat was calculated (77). Systolic and diastolic blood pressures were 
measured by manual sphygmomanometer in a seated position. 
 
Demographic and Life Style Variables 
A standardized questionnaire was administered at baseline to collect information on 
socio-demographic variables including age, gender, self-identified race and years of education, 
and lifestyle variables including smoking status and average alcohol consumption (0,1-2 or >2 
drinks/day) during the past year. Cigarette packs smoked per day were multiplied by the 
number of years of smoking to calculate the pack-years over a lifetime of cigarette smoking. 




designed for the Health ABC study. The frequency, duration, and intensity level of activities 
such as self-report of walking and exercise were recorded, and approximate values of 
metabolic equivalent unit (MET) were assigned to each activity category to estimate weekly 
energy expenditure in kcal/kg/week (78). 
 
Outcome Variable  
In Health ABC metabolic syndrome at year 6, was defined according to the National 
Cholesterol Education Program, Adult Treatment Panel III (NCEP ATP III) as the presence of 
3 or more of the 5 risk components as follows: 1) waist circumference >102 cm for men and 
>88 cm for women; 2) TG =150 mg/dl; 3) HDL-C <40 mg/dl for men and <50 mg/dl for 
women; 4) blood pressure (BP) = 130/85 mmHg or currently on antihypertensive medicine(s); 
5) fasting glucose =110 mg/dl or currently using anti-diabetic (insulin or oral agents) 
medication.  
 
Statistical Analysis  
Serum leptin values and body fat vary by gender, therefore, the analysis were 
performed separately by gender. Observations were grouped according to the quintiles of 
serum leptin level. Baseline characteristics of men and women were examined by quintiles of 
serum leptin levels. For continuous variables Dunnett’s test and for categorical variables chi-
square test was used to compare the means of quintiles 2 through 5 to those of quintile 1. All 
adipokines were log transformed because they were not normally distributed. The interaction 
of serum leptin with race, pro-inflammatory cytokines, and adiposity measures were tested and 
found to be non significant. Multivariate logistic regression modeling was used to determine 
the association between baseline serum leptin and risk of developing metabolic syndrome at 
year 6 follow up. Persons in quintiles 2 through 5 of serum leptin were compared with those in 




study site, education, smoking status, alcohol use, physical activity, calorie intake, hormonal 
replacement therapy and number of hours fasted when blood was drawn), markers of systemic 
inflammation (CRP, TNF- a, IL-6 and PAI-1) and body fat (abdominal fat, total fat percent, 
BMI). The final model included the main predictor variable and covariates that were 
significantly associated with the outcome. Log transformed leptin was used in regression 
model for trend analysis. To further study the effect of body adiposity on the association of 
serum leptin with metabolic syndrome, stratified by two BMI categories (BMI = 25 and 
BMI>25), multivariate logistic regression analysis were run by BMI categories adjusting for 
potential confounders. Statistical significance was set at p = 0.05, and analysis was performed 






There was a significant difference (p<0.0001) between the mean serum leptin 
concentrations among men 7.1 (±5.8) and women 18.7 (±13.3). Baseline characteristics 
indicate that among men, those in quintile 1 had significantly lower BMI, total fat percent, 
abdominal visceral and subcutaneous fat as compared to those in quintile 2, 3, 4, and 5 (Table 
4.1). Individuals with leptin in quintile 1 also had significantly lower abdominal circumference 
than those in quintile 3, 4, 5 and lower fasting glucose, C- reactive protein and PAI-1 than 
quintile 4 and 5. Additionally, men in quintile 1 had significantly lower IL-6 than men in 
quintile 4 and lower TNF-a than men in quintile 5. 
The baseline characteristics of women are shown in Table 4.2. Women in quintile 1 
had significantly lower BMI, total fat percent, abdominal visceral and subcutaneous fat than 
women in all other quintiles. The number of whites in quintile 1 was significantly higher as 
compared to quintile 3 and 4. Those in quintile 3 and 4 were less likely to complete high 
school than those in quintile 1. Women in quintile 1 also had significantly lower IL-6 than 
women in quintile 4 and lower TNF-a than women in quintile 5. Additionally, quintile 1 had 
significantly lower systolic blood pressure than quintile 2 and significantly lower fasting 
glucose, C- reactive protein and PAI-1 than quintile 4 and 5. 
In multivariate analysis, men in quintile 5 of serum leptin were at higher odds (OR = 
2.69; 95% CI = 1.29 – 5.64) of developing metabolic syndrome at year 6 as compared to those 
in quintile 1 after adjusting for potential confounders. However, when the analysis was 
additionally adjusted for BMI and cytokines (model 2 and 3, respectively), serum leptin was 
no longer associated with the risk of metabolic syndrome (Table 4.3). 
Among women, those in quintile 2 (OR = 0.46; 95% CI = 0.24 - 0.85) and 3 (OR = 
0.45; 95% CI = 0.24 - 0.83) of serum leptin were at lower risk of metabolic syndrome than 




(OR = 0.61; 95% CI = 0.30 - 1.22) and 3 (OR = 0.55; 95% CI = 0.28 - 1.07) of serum leptin 
were no longer at lower risk of metabolic syndrome in model 2 compared to women in quintile 
5. With the further adjustment for proinflammatory cytokines in model 3, women in quintile 2 
(OR = 0.65; 95% CI = 0.32 - 1.32) and 3 (OR = 0.58; 95% CI = 0.29 - 1.14) of serum leptin 
were still not at lower risk of metabolic syndrome than women in quintile 5 of serum leptin. 
Women in quintiles 2 (OR = 3.29; 95% CI = 1.36 - 7.95), 3 (OR = 3.25; 95% CI = 1.33 - 
7.93), 4 (OR = 5.21; 95% CI = 2.16 - 12.56), and 5 (OR = 7.97; 95% CI = 3.30 - 19.24) of 
serum leptin were at higher odds of developing metabolic syndrome at year 6 as compared to 
those in quintile 1 after adjusting for potential confounders. In model 2, when the analysis was 
additionally adjusted for BMI individuals whose leptin values were in quintiles 2-5, were still 
at higher odds of developing metabolic syndrome at year 6 as compared to quintile 1 (OR = 
3.04; 95% CI = 1.21 - 7.62, OR = 2.94; 95% CI = 1.12 - 7.71, OR = 4.56; 95% CI = 1.65 - 
12.61, and OR = 6.38; 95% CI = 2.09 - 19.42), respectively. Adjusting for cytokines in 
addition to BMI and other potential confounders in model 3, did not affect the significance of 
the positive association between serum leptin and the risk of metabolic syndrome at year 6. 
There was a significant positive trend between metabolic syndrome risk and the serum leptin 
quintiles in model 1 (p=0.0001), 2 (p=0.0024), and 3 (p=0.0098) (Table 4.4).  
Association of serum leptin with metabolic syndrome may be confounded by body 
adiposity due to its correlation with serum leptin. Therefore, to examine the independent 
relationship between serum leptin and risk of metabolic syndrome, the sample was stratified 
by 2 BMI categories (BMI = 25 and BMI > 25). Among women, serum leptin was 
significantly associated with the risk of metabolic syndrome at year 6 in both BMI groups after 
adjusting for potential confounders. Among men, no association was found in either BMI 
category between serum leptin and metabolic syndrome after adjusting for potential 






In the present study, serum leptin concentrations were associated with the risk of 
developing metabolic syndrome among older women independent of age, race, site, education, 
physical activity, smoking, drinking, hormonal replacement therapy, and hours of fasting. 
These associations remained significant when the measures of body adiposity and the pro-
inflammatory cytokines were controlled for. Women in quintile 1 of serum leptin levels were 
at lower risk for developing metabolic syndrome as compared to women in all other quintiles.  
Some longitudinal studies of serum leptin and metabolic disease have found a 
significant positive association. In middle -age men, serum leptin formed a part of the cluster 
that constituted insulin resistance and hyperinsulinemia independent of measures of body fat 
(40). Franks et al., in the Medical Research Council Ely Study of middle age subjects, found 
leptin to be positively related to the metabolic syndrome risk after adjusting for obesity (79). 
Several cross-sectional studies have linked serum leptin levels to individual components of the 
metabolic syndrome (40, 42, 17, 18, 19, 80, 81 and 132). High blood pressure and serum 
insulin have been shown to be positively associated with hyperleptinemia, while serum 
triglyceride level was negatively associated (18, 17, 19, 80, and 81). A study on hypertensive 
older adults reported that serum leptin and systolic blood pressure are positively associated 
among women while serum leptin is associated with diastolic blood pressure among men (81). 
Although, leptin has been shown to stimulate the production of the pro-inflammatory 
cytokines (39) that are linked to obesity (44), process of aging (7), atherogenic activity (76) 
and metabolic syndrome (7 and 76), contribution of the pro-inflammatory molecules to the 
association of serum leptin and metabolic syndrome was not explored in the aforementioned 
studies. 
Due to the structural and functional similarities of leptin and its receptor with the IL-




(38).  Enhanced production of pro-inflammatory cytokines, IL-6, TNF- a, CRP, has been 
implicated in the development of metabolic syndrome (40, 89 and 90) and diabetes (135). CRP 
and IL-6 predict the future coronary artery disease (40 and 51) and serum leptin has been 
suggested to be independently associated with production of C- reactive protein (39 and 139). 
Although serum leptin has been linked to proinflammatory cytokines, we found a significant 
association between hyperleptinemia and metabolic syndrome risk independent of 
proinflammatory cytokines among women, suggesting the potential role of leptin resistance in 
the development of metabolic disorders.  
In the current study, serum leptin remained a potential predictor of metabolic 
syndrome among individuals with BMI below 25 and those above it, after adjusting for 
potential confounder among women. In men, the association between serum leptin and the risk 
of metabolic syndrome appeared to be dependent on body adiposity.  
Previous studies on the role of adiposity on the association of serum leptin and 
metabolic disorders have shown inconsistent results. The Atherosclerosis Risk in Communities 
(ARIC) study showed the protective effect of elevated leptin on incident diabetes after 
adjusting for potential confounders and adiposity among both men and women (45), whereas, 
an inverse association between elevated leptin and the risk for subsequent diabetes was found 
to be mediated by adiposity and insulin insensitivity among Japanese men (82). A cross-
sectional study on Iranian population found an association between serum leptin, insulin 
resistance and metabolic syndrome to be dependent on central obesity (138). However, 
analysis was not performed by gender in this study. A recent study from National Health and 
Nutrition Examination Survey (NHANES) on United States population found a positive 
association between higher serum leptin and mayocardial infarction or stroke independent of 
obesity (83). 
In addition to the current study, several other studies have suggested that there may 




adiposity. As compared to men, elevations in serum leptin and the association between serum 
leptin and insulin resistance was shown to be independent of total fat mass (84) and BMI (17) 
among women. Furthermore, in a study on older men, the association of serum leptin with 
diabetes was mediated by obesity and insulin resistance (49) and the association of serum 
leptin with lipid parameters was mediated by BMI (40). Compared to older men, higher serum 
leptin concentrations in older women were not fully explained by visceral and subcutaneous 
adipose tissues measured by magnetic resonance imaging (MRI) (87) and computed 
tomography (88).Women have been consistently shown to have higher serum leptin 
concentrations independent of total body fat mass or percent fat (85, 86, and 72) and it has 
been proposed that elevated levels of serum leptin can lead to the development of leptin 
resistance (74 and 129) suggesting that women may be more leptin resistant as compared to 
men. Thus, the sex difference in the association of serum leptin with metabolic syndrome in 
our study may be explained by relatively greater leptin insensitivity in women. 
Leptin exerts its effects both centrally and peripherally , as it has receptors in the 
hypothalamus as well as in peripheral organs. Centrally, it affects energy intake and 
expenditure, body weight and neuro-endocrine functions. In liver and muscle it activates 5’ - 
Adenosine Mono Phosphate – activated Protein Kinase (AMPK), which inhibits acetyl-CoA 
carboxylase and increases fatty acid oxidation (145). Activated AMPK also decreases glucose 
regulated transcription, protein synthesis, cholesterol synthesis, triglyceride synthesis and 
increases glucose transport and glycolysis (74). Several theories have been proposed to explain 
the mechanism for leptin resistance. Leptin stimulates the production of cytokine signaling 3 
suppressors (SOCS-3), which inhibits the leptin signaling by its effect on leptin receptor 
OBRb. The leptin receptor activates Janus kinase–signal transducers and activators of 
transcription (JAKSTAT) pathway via STAT3 proteins to provide intracellular signaling 
(143). The leptin stimulated SOCS-3 down regulates the JAKSTAT pathways and inhibits 




abdominal adiposity during aging, as well as an increase in insulin resistance, suggesting that 
it could be a mediator of leptin resistance in aging individuals (9, 10, 11, 12, 129 and 130). 
Leptin resistance in brain leads to excess triglyceride accumulation in adipose tissue, liver, 
muscles and pancreas, resulting in impaired insulin sensitivity and secretion (146). Thus, the 
relatively greater leptin insensitivity among women in our study may be explained by elevated 
serum leptin levels among women (85, 86, and 72) , which may impair leptin signaling due to 
increased production of SOCS-3 resulting in leptin resistance (143) and accumulation of body 
fat. 
The strength of this study includes the evaluation of the prospective association 
between the serum leptin and the metabolic syndrome as the data were collected in several 
waves in Health ABC. Because in the HABC study extensive information was collected on life 
style and biochemical variables, it was possible to adjust for many potential confounders such 
as the use of hormonal replacement therapy, number of hours fasted when the blood was 
drawn, total calorie intake, physical activity unlike the previous studies which adjusted for few 
confounders. Also, analysis was limited to the variables available in Health ABC. Information 
on metabolic syndrome variable was available only for baseline and year 6, so metabolic 
syndrome at year 6 was included in the analysis. Due to the unavailability of longitudinal data 
on serum insulin it was not possible to explore the prospective association of serum leptin and 
insulin resistance. 
In conclusion, the current study suggests that serum leptin is prospectively 
associated with the development of metabolic syndrome independent of body adiposity and 
pro-inflammatory markers among older women. Because the prevalence of metabolic 
syndrome increases with aging and hyperleptinemia has been linked to metabolic syndrome 
and its components including blood pressure, adiposity and insulin sensitivity, elevated serum 




older women. If leptin resistance occurs due to hyperleptinemia, leptin sensitizing drugs may 






Table 4.1 Baseline Characteristics of Men by Serum Leptin Quintile  1 
                                                                                                                             Serum Leptin Quintile                                                                   
                                                                   1 2 3 4 5 
Men (n (%)) 110 (19.9) 110 (19.9) 111 (20.1) 110 (19.9) 111 (20.1) 
Mean Serum Leptin  (ng/ml) 3 2.14 (±0.05) 3.78 (±0.05) 2 5.61 (±0.06) 2 8.13 (±0.09) 2 15.81 (±0.75)  2 
Demographic and behavioral variables      
Age (years) 3 75.4 (±0.29) 75.1 (±0.25) 74.9 (±0.29) 75.1 (±0.28) 75.2 (±0.28) 
Race (% white) 68 70 74 65 61 
Drinking  (% any consumption) 65 69 63 58 61 
Education (% completed high school) 74 79 75 76 81 
Smoking (lifetime pack-years) 3 18.87 (±2.41) 19.1 (±2.44) 23.9 (±3.05) 20.9 (±3.15) 22.87 (±2.91)2 
Physical activity (kcal/kg/week)  3 10.2 (±1.87) 12.89 (±2.69) 8.08 (±1.48) 9.97 (±2.10) 8.55 (±1.43) 
Dietary and anthropometric variables      
Total calorie intake (kcal) 4 2197 (±90.4) 1966 (±79.4) 2055 (±75.7) 2014 (±78.2) 2124 (±96.1) 
BMI (kg/m2) 3 23.76 (±0.22)   25.16 (±0.20)  2 26.15 (±0.25)  2 27.44 (±0.27)  2 29.11 (±0.38)  2 
Abdominal circumference (cm) 3 91.29 (±0.67) 95.26 (±0.59) 98.3 (±0.69) 2 101.9 (±0.67)  2 105.32 (±0.94)  2 
Abdominal visceral fat (cm2) 3 103.2 (±3.9) 123.9 (±4.4) 2 140.6 (±4.5) 2 154.57 (±5.5)  2 183.98 (±7.5)  2 
Abdominal subcutaneous fat (cm2) 3 149 (±4.21) 190 (±4.1) 2 213.61 (±5.4)  2 248.8 (±6.7) 2 276.91 (±7.9)  2 
Total body fat (%)3 24.4 (±0.26) 27.5 (±0.30) 2 28.82 (±0.27)  2 31.05 (±0.32)  2 32.86 (±0.42)  2 
Clinical and biochemical variables      
Diastolic Blood pressure (mmHg) 3 71.9 (±1.23) 71.8 (±1.07) 71.97 (±1.25) 74.2 (±1.09) 74.1 (±1.24) 
Systolic Blood pressure (mmHg)3 132 (±1.81) 133 (±2.19) 133.2 (±1.9) 135.8 (±2.03) 132.1 (±2.29) 
Fasting glucose (mg/dl) 3 95.4 (±2.63) 97 (±2.58) 99.02 (±2.5) 97.4 (±1.92) 2 99.6 (±1.7) 2 
HDL cholesterol (mg/dl) 3 52.2 (±1.24) 50.6 (±1.2) 48.3 (±1.1) 48.5 (±1.1) 50.2 (±0.98) 
Triglycerides (mg/dl) 3 104.5 (±4.1) 102.6 (±3.97) 115.3 (±4.3) 114.4 (±5.1) 116.2 (±4.2) 
C-reactive protein (µg/ml) 3 1.74 (±0.23) 2.03 (±0.3) 1.94 (±0.23) 2.26 (±0.24) 2 2.07 (±0.16) 2 
PAI-1 (ng/ml) 3 17.93 (±1.55) 17.9 (±1.25) 24.6 (±1.8) 22.29 (±1.5) 2 29.8 (±2.0)  2 
Clinical and biochemical variables      
IL-6 (pg/ml) 3 1.98 (±0.17) 2.08 (±0.14) 2.14 (±0.18) 2.15 (±0.15) 2 2.01 (±0.12) 




1 Means (±SEM) are provided in the table unless specified.  
2 Significantly different from leptin quintile 1, P=0.05 (Dunnett’s test for continuous variables and chi-square test for categorical variables). 
3 Values from baseline of the Health ABC study 




Table 4.2 Baseline Characteristics of Women by Serum Leptin Quintile 1  
                       Serum Leptin Quintile      
  1 2 3 4 5 
Women (n (%)) 113 (19.9) 114 (20.7) 113 (19.9) 114 (20.7) 114 (20.7) 
Mean Serum Leptin (ng/ml) 3 5.24 (± 0.21)  10.01 (± 0.11) 2 15.28 (± 0.18) 2 21.97 (± 0.23) 2 39.67 (± 1.1) 2 
Demographic and behavioral factors       
Age (years) 3 75.35 (±0.30) 75.35 (±0.30) 75.05 (±0.29) 74.76 (±0.27) 75.27 (±0.28) 
Race  (% white) 80 73 71 452 412 
Drinking (% any consumption) 44 49 50 45 42 
Education (% completed high school) 88 87 84  71 2 78 2 
Smoking (lifetime pack-years) 3 13.5 (±2.5) 8.29 (±1.70) 12.7 (±2.3) 11.3 (±2.27) 5.752 (±1.43) 
Physical activity (kcal/kg/week)  3 5.52 (±1.04) 5.75 (±1.05) 5.72 (±1.24) 2.83 (±0.65) 7.31 (±2.76) 
Dietary and anthropometric variables      
Total calorie intake (kcal) 4 1612 (±63.6) 1793 (±85.4) 1650 (±68.0) 1690 (±67.3) 1654 (±64.9) 
BMI (kg/m2) 3 22.16 (±0.32) 24.17 (±0.31)2 25.66 (±0.34)2 27.9 (±0.41)2 30.3 (±0.46)2 
Abdominal circumference (cm) 3 84.74 (±1.06) 88.9 (±0.98) 95.5 (±1.08)2 99.7 (±1.56)2 103.88 (±1.33)2 
Abdominal visceral fat (cm2) 3 78.6 (±3.8) 104.3 (±4.6)2 109.3 (±4.56)2 121 (±4.2)2 139.45 (±4.74)2 
Abdominal subcutaneous fat (cm2) 3 219.9 (±8.3) 267 (±7.8)2 306.2 (±9.1)2 370 (±9.5)2 418.12 (±11.3)2 
Total body fat (%)3 34.18 (±0.52) 38 (±0.43)2 39.76 (±0.39)2 42.3 (±0.35)2 44.7 (±0.37)2 
Clinical and biochemical variables      
Diastolic Blood pressure (mmHg) 3 69 (±1.1) 71 (±1.13) 66.94 (±1.2) 71 (±1.09) 68.5 (±1.1) 
Systolic Blood pressure (mmHg)  3 130 (±2.14) 137 (±2.01)2 131.1 (±1.9) 135 (±2.1) 132.2 (±2.19) 
Fasting glucose (mg/dl) 3 87 (±0.84) 91 (±1.6) 91.2 (±1.8) 92.8 (±1.1)2 92.0 (±0.78)2 
HDL cholesterol (mg/dl) 3 67 (±1.37) 68 (±1.7) 64.9 (±1.48) 63.7 (±1.49) 64.3 (±1.44) 
Triglycerides (mg/dl) 3 101.45 (±3.7) 113 (±4.99) 113 (±5.0) 110.4 (±4.20) 111.7 (±4.31) 
C-reactive protein (µg/dl) 3 1.52 (±0.16) 2.33 (±0.31) 2.27 (±0.18) 3.18 (±0.33)2 3.3 (±0.56)2 
PAI-1 (ng/ml) 3 17.5 (±1.43) 24.3 (±2.57)         22.2 (±2.10) 28.9 (±2.10)2 27.5 (±2.18)2 
IL-6 (pg/ml) 3 1.78 (±0.16) 1.74 (±0.16) 1.96(±0.21) 2.67 (±0.28)2 2.17 (±0.18) 
TNF-alpha (pg/ml) 3 2.76 (±0.11) 2.98 (±0.11) 2.94 (±0.11) 3.13 (±0.12) 3.31 (±0.25)2 
1 Means (±SEM), unless otherwise specified. 
2 Significantly different from leptin quintile 1, P=0.05 (Dunnett’s test for continuous variables and chi-square test for  categorical variables). 
3 Values from baseline of the Health ABC study 





Table 4.3 Adjusted Odd Ratios (OR) of the Metabolic Syndrome by Serum Leptin Quintile 
Among Men 
                                                                        Serum Leptin Quintile                                                      
  1 2 3 4 5 p value 
Men (n) 110 110 111 110 111   
Serum leptin 
quintile (mean ± 
SD) 
2.11 
(±0.511) 3.74(±0.49) 5.55 (±0.65) 8.09(±0.90) 15.82(±7.35)  <0.0001 
Metabolic 
syndrome cases (n) 13 11 18 23 29 0.0076 
 
Model 1 
OR (95% CI) 1 
0.83  
(0.35 - 1.98) 
1.36  
(0.62 - 2.99) 
1.88 
 (0.87 - 4.05) 
2.69  
(1.29 - 5.64) 0.0002 
 
Model 2  
OR (95% CI) 1 
0.63  
(0.25 -  1.58) 
 
  0.90  
(0.38 -  2.14) 
  
1.01  
(0.40 -  2.54) 
1.03  
(0.37 - 2.86) 0.1435 
 
Model 3  
OR (95% CI) 1 
0.65  
(0.26 -  1.63) 
0.73 
 (0.30 - 1.76) 
0.77 
 (0.29 -  2.01) 
0.68
 (0.23 - 2.01) 0.5034 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity 
(testosterone level and numbers of hours fasted were not significant and did not affect the association 
between predictor and outcome, so they were not included in the model) 
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, and BMI 
(Effect of total percent fat, visceral fat, subcutaneous fat on the association between main predictor and the 
outcome were similar to BMI, so they were not included in the final analysis)  
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, BMI, 
CRP, and PAI-1 (TNF-alpha and IL-6 were not significant and did not affect the association between main 













Table 4.4 Adjusted Odd Ratios (OR) of the Metabolic Syndrome by Serum Leptin Quintile  
Among Women 
                                                                        Serum Leptin Quintile                                                                    
  1 2 3 4 5 p value 
Women (n) 113 114 113 114 114   
Serum leptin 





 (± 1.12) 
15.18 




(± 10.45) <0.0001 
Metabolic 
syndrome cases 
(n) 8 21 20 27 34 0.0003 
 
Model 1  
OR (95% CI) 1 
3.29 






(3.30 - 19.24) <0.0001 
Model 2 
OR (95% CI) 1 
 
3.04 






 (2.09 - 19.42) 0.0024 
 
Model 3 
OR (95% CI) 1 
2.85 




(1.53 - 11.7) 
5.96  
(1.95 - 18.13) 0.0098 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity (hormonal 
replacement therapy and numbers of hours fasted were not significant and did not affect the association 
between predictor and outcome, so they were not included in the model)  
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, and BMI 
(Effect of total percent fat, visceral fat, subcutaneous fat on the association between main predictor and the 
outcome were similar to BMI, so they were not included in the final analysis )  
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, BMI, 
CRP, and PAI-1 (TNF-alpha and IL-6 were not significant and did not affect the association between main 










      
Table 4.5 Adjusted Odd Ratios (OR) of Metabolic Syndrome by BMI Category 
  BMI <=25 (Normal) BMI > 25 (High) 
Men (n) 210 372 
Mean Serum Leptin (mean ± SD) 4.61 (±3.5) 8.44 (±6.3) 
Metabolic Syndrome Cases (n) 18 91 
OR (95% CI) 1.08 (0.49 - 2.40) 1.32 (0.90 - 1.94) 
Women (n) 267 329 
Mean Serum Leptin (mean ± SD) 11.44 (±8.8) 24.50 (±13.6) 
Metabolic Syndrome Cases (n) 37 91 
OR (95% CI) 2.10 (1.20 - 3.67) 2.00 (1.22 - 3.26) 









Background: Elevated levels of serum leptin are associated with measures of adiposity 
and increased production of pro-inflammatory cytokines. Both cytokines and body adiposity have 
been shown to predict cardiovascular events and mortality.  
Objectives: The primary objective of the present study was to explore the associations 
between serum leptin and all-cause mortality and mortality from CVD over a span of 10 years 
controlling for body adiposity and proinflammatory cytokines. A secondary objective was to 
examine the association between serum leptin and diabetes as a contributing cause of mortality 
stratified by leptin receptor genotype. 
Design:  The Health, Aging and Body Composition (HABC) study is a prospective 
cohort of 3,075 older adults aged 70 to 79 years. All-cause mortality and incident cardiac events 
(CHD and HF) were detected from baseline through year 10. Participants, genetic variation in the 
leptin receptor gene were identified. Variables of body adiposity and markers of systemic 
inflammation were assessed in detail.  
Results: As compared to women in quartile 1, those in quartile 3   were at lower risk of 
all-cause mortality and those in quartile 2 and 3 were at lower risk of mortality from CVD 
independent of proinflammatory cytokines and total percent fat. A significant trend for diabetes 
as a contributing cause of mortality was found after adjusting for potential confounders (p=0.01), 




Additionally, there was a significant interaction between leptin receptor genotype and total 
percent fat in association with diabetes as a contributing cause of mortality among older women 
(p=0.03). 
Conclusion: The present study suggests a paradoxical association between leptin, 
cardiovascular risk factors and mortality from CVD. Intermediary concentrations of serum leptin 
are associated with lower risk of all-cause mortality and mortality from CVD, while elevated 
levels increase the risk of diabetes as a contributing cause of death among older women. An 
interaction was found between leptin receptor genotype and body fat, which may lower the risk of 




Serum leptin and proinflammatory cytokines have been implicated in the development of 
several age-associated chronic conditions such as atherosclerosis, insulin resistance, diabetes and 
osteoporosis (34, 51, 52, 53 54, 84, 89 and 96). Leptin plays a critical role in energy intake (55 
and 56), inflammatory response (35) and is strongly correlated with body fat (9, 35, 58 and 59), 
all of which are linked to mortality (34). This suggests a potential association between serum 
leptin and mortality.  
There is a concomitant increase in the levels of serum leptin, proinflammatory cytokines 
(34, 35, and 95) and prevalence of metabolic diseases with aging (6, 47, 55, 92 and 96). Leptin 
and its receptor have structural and functional similarities with the IL-6 family of cytokines (54). 
Leptin has been shown to be associated with increased production of the pro-inflammatory 
cytokines (61 and 95) that are linked to obesity (55), the process of aging (40), atherogenic 
activity (97) and metabolic syndrome (40, 79 and 97). High levels of IL-6 were associated with 




concomitant increase in TNF- a and serum leptin with aging has been associated with obesity and 
atherosclerosis (7 and 38).  
Although serum levels of leptin have been consistently shown to be associated with 
increased inflammation and morbidity, previous studies have not explored the association of 
leptin with survival while controlling for inflammatory factors and body adiposity among 
functionally well older adults. 
The primary objective of this study was to examine the association between serum leptin 
and the risk of all-cause mortality and mortality from CVD over a 10-year follow-up and to 
investigate whether these associations are mediated by markers of inflammation and body fat. 
The other objective was to examine the association between serum leptin and diabetes as a 
contributing cause of mortality stratified by leptin receptor genotype. 
 
Subjects and Methods  
Study Design 
The Health, Aging and Body Composition (Health ABC) study is a longitudinal cohort 
study of 3,075 community dwelling, well functioning white and black men and women aged 70 to 
79 years at the commencement of the study. This study was described in details elsewhere (91). 
Briefly, participants were recruited for the study from a random sample of white residents 
receiving Medicare benefits and all age-eligible black residents of Pittsburgh, Pennsylvania, and 
Memphis, Tennessee. The subjects were considered eligible to participate in the study if they 
reported no difficulty walking a quarter of a mile, climbing 10 steps without resting, or 
performing basic activities of daily living, were free of life-threatening illness, and planned to 
remain in the geographic area for at least 3 years. Those who reported active treatment for cancer 
or participation in diet or exercise intervention were excluded from the study. Participants gave 




two study sites.  A home interview was administered to the study participants to collect 
information on demographic, socioeconomic factors, and health behaviors. A clinic visit at 
baseline was conducted for examination of biological variables, body composition, weight-related 
health conditions, and physical function between April 1997 and June 1998.  Thereafter, follow-
up clinical examinations have been conducted annually, and interviews semi-annually. 
 
Subjects  
In the present study data from baseline through year 10 of the Health ABC study were 
used. The sample size for the present study was 2,919 (men = 1,419; women = 1,500) after 
excluding those with incomplete information for vital status (n =101) and missing values for 
serum leptin (n = 55). 
 
Biochemical Variables 
Participants underwent venipuncture at baseline visit after an overnight fast, and serum 
samples were frozen at -70°C. Plasma glucose was measured using an automated glucose oxidase 
reaction (YSI 2300 Glucose Analyzer; Yellow Springs Instruments, Yellow Springs, OH). Both 
IL-6 and TNF- a were measured in duplicate using an ultrasensitive enzyme-linked 
immunosorbent assay (R&D Systems, Minneapolis, Minn). The limit of detection was 0.10 pg/ml 
for IL-6 and 0.18 pg/ml for TNF- a. The level of plasminogen activator inhibitor-1 (PAI-1) was 
measured in citrated plasma samples using a 2-site enzyme-linked immunosorbent assay 
according to previously published methods (91). Serum levels of CRP were also measured in 
duplicate by enzyme-linked immunosorbent essay based on purified protein and polyclonal anti-
CRP antibodies (Calbiochem, San Diego, California) with a coefficient of varia tion of 8.0%. 
Serum concentrations of leptin were measured in duplicate by means of radioimmunoassay 
(Linco Research Inc, St Charles, Mo). The assay range is 0.05 to 100 ng/ml leptin in serum or 




8.9%. The assay is highly specific for human leptin and shows minimal reactivity with mouse or 
rat leptin (91). 
 
Anthropometric Variables 
Weight was measured using a standard balance beam scale in kilograms. Height was 
measured twice using a Harpenden stadiometer (Holtain Ltd., Crosswell, U.K.) in centimeters and 
the average of the two measurements was used. Dual energy x-ray absorptiometry (DXA) 
(Hologic QDR 4500A, software version 8.21, Hologic, Waltham, MA) was used to assess the 
total fat mass. The total percentage of body fat was calculated (77).  
 
Demographic and Life Style Variables 
A standardized questionnaire was administered at baseline to collect information on 
socio-demographic variables including age, gender, self-identified race and years of education, 
and lifestyle variables including smoking status and average alcohol consumption during the past 
year (0,1-2 or >2 drinks/day). Cigarette packs smoked per day were multiplied by the number of 
years of smoking to calculate the pack-years over a lifetime of cigarette smoking. Level of 
physical activity was ascertained by a standardized questionnaire specifically designed for the 
Health ABC study. The frequency, duration, and intensity level of activities such as self-report of 
walking and exercise were recorded, and approximate values of metabolic equivalent unit (MET) 




TaqMan polymerase chain reaction was used to genotype the entire Health ABC cohort, 
for identifying 3’untranslated region pentanucloetide insertion/deletion polymorphism of leptin 





Outcome Variable  
In Health ABC, mortality outcomes were assessed from baseline through November 26, 
2007. The study outcome measures were all-cause mortality, mortality from CVD and from 
diabetes as a contributing cause of mortality. Immediate and underlying causes of death were 
adjudicated by a central committee using established criteria. Deaths were ascertained through the 
review of the death certificate, hospital records, proxy interviews and Social Security Death Index 
data. Survival time was defined as the time from the baseline visit until the date of first event 
(death or cardiac event) and/or date of last contact. Mortality from CVD was defined as any death 
where the underlying cause of death was confirmed as atherosclerotic cardiovascular disease 
(definite fatal myocardial infarction, or definite or possible fatal coronary artery disease), 
cerebrovascular disease, and atherosclerotic disease other than cardiovascular, and other 
cardiovascular disease. The sample size was too low for analysis of mortality from T2D by serum 
leptin quartile. Therefore, diabetes as a contributing cause of mortality was defined as any death 
where the participant was suffering from T2D (previously and newly diagnosed diabetes). 
Participants were contacted every 6 months through in-person examinations or telephone 
interviews during which time their health status was assessed. 
 
Statistical Analysis  
Serum leptin values and body fat vary by gender; therefore, the analysis was performed 
separately by gender (72). Baseline characteristics of men and women were examined by 
quartiles of serum leptin. For continuous variables Dunnett’s test and for categorical variables 
chi-square test were used to compare the means of quartile 2 through 4 to those of quartile 1. All 
adipokines were log transformed because they were not normally distributed. The interaction of 
serum leptin with race, pro-inflammatory cytokines, and adiposity measures were tested and 




Cox proportional hazard regression analysis was used to assess the risk of all-cause 
mortality and mortality from cardiovascular for persons in quartiles 2 through 4 of serum leptin 
compared with those in quartile 1. Three regression models were run which sequentially adjusted 
for potential confounders (age, gender, race, study site, education, smoking status, alcohol use, 
and physical activity), total percent fat and markers of systemic inflammation (CRP, TNF- a, and 
IL-6). Final model included the main predictor variable and covariates that were significantly 
associated with the outcome. Log transformed leptin was used in regression model for trend 
analysis. All the covariates met the assumptions for proportional hazard regression.  
The association between the 3’ un-translated region (UTR) insertion/deletion 
polymorphism of the leptin receptor gene and the risk of diabetes as a contributing cause of 
mortality were examined before and after addition of the total percent fat to the model. The leptin 
receptor genotype was dichotomized for deletion/deletion (D/D), and for I allele (insertion/ 
deletion and insertion/insertion genotypes combined). An interaction term was created to check 
the interaction between leptin receptor genotype and total percent fat after adjustment for 
potential confounders. The frequency of leptin receptor (I/I) and (I/D) genotype differed 
significantly by race in the present study and gender dimorphism has been reported in the 
expression of leptin receptor in skeletal muscles in the previous study (107), therefore, analysis 
was performed separately by race and gender. Statistical significance was set at p = 0.05, and 
analysis was performed using SAS (version 9.1; SAS Institute Inc., Cary, NC). 
 
Results  
There was a significant difference (p<0.0001) between the mean serum leptin 
concentrations among men 7.9 (±6.9) and women 21.3 (±14.6). Baseline characteristics indicate 
that among men and women, those in quartile 1 had significantly lower serum leptin levels, BMI 




with leptin in quartile 1 had significantly lower TNF-a than those in quartile 4.  Women in 
quartile 1 also had significantly lower CRP and IL-6 levels than those in quartile 3 and 4. Both, 
men and women in quartile 4 of serum leptin had lower percent of alcohol consumption and 
higher T2D mortality than those in quartile 1. Men in quartile 3 were more likely to be white, 
complete high school and had lower all-cause mortality as compared to those in quartile 1. 
Women in quartile 2, 3, and 4 were less likely to be white and those in quartile 3 and 4 and were 
less likely to complete high school as compared to those in quartile 1. 
Tables 5.3 and 5.4 show characteristics of the men and women, respectively, according 
to leptin receptor genotype and race. White men with leptin receptor (D/D) genotype had 
significantly higher CRP than those with leptin receptor (I/I) and (I/D) genotype. White women 
with leptin receptor (D/D) genotype were more likely to consume alcohol than those with leptin 
receptor (I/I) and (I/D) genotype. Black women with leptin receptor (D/D) genotype had 
significantly lower diabetes as a contributing cause of mortality than those with leptin receptor 
(I/I) and (I/D) genotype.  
The average follow-up time from baseline was 8.4 years, with a range of 1.1 to 10.4 
years. During the follow-up time, 556 (39.2%) men and 401 (26.7%) women died due to all-cause 
mortality. Table 5.5 shows the relative risk of all-cause mortality according to the serum leptin 
quartile among men and women. Association between risk of all-cause mortality and serum leptin 
levels among men was not statistically significant. Among women, those in quartile 2 (RR = 
0.71; 95% CI = 0.53, 0.95) and 3 (RR = 0.73; 95% CI = 0.55, 0.98) had significantly lower risk of 
mortality as compared to those in quartile 1 after adjusting for potential confounders in model 1. 
When the analysis was additionally adjusted for total percent fat in model 2, the associations were 
no longer significant. With further adjustment with proinflammatory cytokines in model 3, 
association between quartile 3 of serum leptin and mortality risk became marginally significant 
(RR = 0.68; 95% CI = 0.47, 0.99). Analysis of trend for the risk of mortality across quartiles of 




During the follow-up time, 197 (13.9%) men and 154 (10.3%) women died due to 
mortality from CVD. (Table 5.6) There was no significant association between risk for mortality 
from CVD and serum leptin levels among men. Women in quartile 2 of serum leptin (RR = 0.60; 
95% CI = 0. 37, 0.97) were at lower risk for mortality from CVD as compared to women in 
quartile 1 after adjustment for potential confounders in model 1. This association was no longer 
significant once adjusted for percent fat in model 2. In model 3, when the analysis was 
additionally adjusted for proinflammatory cytokines women in quartile 2 (RR = 0.48; 95% CI = 
0. 27, 0.86) and 3 (RR = 0.50; 95% CI = 0. 27, 0.92) were at lower risk for mortality from CVD 
as compared to those in quartile 1. No significant trend for the risk of mortality from CVD across 
serum leptin quartiles was shown among men and women. 
During the follow-up time, 171 (12.1%) men and 115 (7.6%) of the women who died had 
diabetes as a contributing cause of mortality. (Table 5.7) Men in quartile 4 of serum leptin had a 
significantly higher risk of mortality from diabetes as a contributing cause of death as compared 
to those in quartile 1 after sequential adjustment for potential confounders and total percent fat in 
model 1 (RR = 2.07; 95% CI = 1.33, 3.25), and 2 (RR = 2.79; 95% CI = 1.49, 5.25). These 
associations were no longer significant once the model was further adjusted for proinflammatory 
cytokines in model 3. There was a significant positive trend for the risk of diabetes as a 
contributing cause of mortality across the serum leptin quartiles in model 1 (p=0.0006) and 2 
(p=0.0003) among men. Among women, those in quartile 4 of serum leptin were at significantly 
higher risk of diabetes as a contributing cause of mortality as compared to those in quartile 1 after 
adjustment for potentia l confounders and total percent fat in model 2 (RR = 2.42; 95% CI = 1.09, 
5.35). With further adjustment for proinflammatory cytokines the association was no longer 
significant. However, there was a significant positive trend for the risk of diabetes as a 
contributing cause of mortality across the serum leptin quartiles in model 1 (p=0.01), 2 




Table 5.8 and 5.9 shows the relative risk of diabetes as a contributing cause of mortality 
stratified by genotype for leptin receptor among black and white men and women. Black women 
with I/I and I/D genotype were at higher risk for diabetes as a contributing cause of mortality (p= 
0.04) as compared to black women in the reference group (D/D genotype) after adjustment for 
potential confounders and total percent fat in model 2. There was a significant interaction 
between leptin receptor genotype and total percent fat in model 3 (p= 0.001) among black 
women. The interaction term remained significantly negatively associated (p= 0.003) with 
diabetes as a contributing cause of mortality after adjusting for proinflammatory cytokines among 
black women in model 4. There was no significant association between leptin receptor genotype 







In the present study intermediate levels of serum leptin were associated with lower risk of 
all-cause mortality and mortality from CVD, while elevated levels were associated with increased 
risk of mortality among individuals with diabetes as a contributing cause of death among women. 
These associations remained significant after controlling for measures of body adiposity and the 
pro-inflammatory cytokines.  
Results of this study are supported by previous studies that have shown an association 
between serum leptin and all-cause and CVD mortality (60 and 61). Lieb et al., in Framingham 
Heart Study found a U-shaped association between serum leptin and all-cause mortality with 
elevated risk of death at both low and high levels of leptin (60). Furthermore, they showed that 
the U-shape association was mainly contributed by increased risk of death due to non-
cardiovascular diseases (60). Hypoleptinemia has been shown to elevate the risk of cancer 
mortality (63), while hyperleptinemia increased the risk of mortality from T2D (62). 
Additionally, in a longitudinal study on middle age women moderately elevated serum leptin was 
inversely associated with CVD mortality after adjusting for adiposity (64). Although leptin has 
been shown to stimulate the production of the pro-inflammatory cytokines (61 and 102) that are 
linked to obesity (100) and chronic diseases (7, 38, and 89), the association of serum leptin, all-
cause mortality and CVD mortality was not explored in context of pro-inflammatory cytokines 
among functionally well older adults in above studies.  
 Previous studies have consistently showed protective effect of leptin on all-cause 
mortality and CVD mortality, however the mechanisms for such associations remain unc lear. It 
has been shown that hyperleptinemia can cause impaired leptin signaling and leptin insensitivity 
leading to storage of fat in muscles and liver (14 and 94). On the other hand, hypoleptinemia has 
been associated with complete or partial absence of subcutaneous fat (58 and 98). Leptin 




and 56) and facilitate accumulation of adipose tissue in body (55 and 93). Body fat forms a U-
shaped association with mortality (103) and being slightly overweight has been associated with 
lower risk of mortality among older adults (103 and 109). Therefore, moderate levels of serum 
leptin may help to maintain optimal body fat and thus, lower mortality risk. Furthermore, 
regulation of energy balance is different among men and women (105 and108) and brains of 
women are relatively more sensitive to leptin as a strategy for weight maintenance (108). Thus, 
the gender difference in the association of leptin with all-cause mortality and CVD mortality may 
be explained by greater sensitivity among women to the effects of leptin for maintaining 
appropriate body fat.  
Previous studies have shown positive association between elevated serum leptin and the 
risk factors for cardiovascular disease among healthy and diabetic individuals (6, 38, 51, 54, and 
110). Paradoxically, elevated leptin has been also shown to reduce cardiomyocyte lipotoxicity by 
promoting fatty acid oxidation (111 and 112) and provides an environment that compensates for 
the reduced cardiac output and improves survival (112). Leptin has receptors on cardiac myocytes 
and it exerts direct antihypertrophic effects in heart by stimulating nitric oxide signaling (113). 
Leptin deficiency or impaired leptin signaling, as in state of leptin resistance, may lead to 
development of left ventricular hypertrophy (113), suggesting that both very low and very high 
levels of serum leptin may lead to cardiac dysfunction. 
Due to the structural and functional similarities of leptin and its receptor with the IL-6 
family of cytokines, leptin appears to play a critical role in the immune response (7).  Enhanced 
production of CRP and IL-6 has been shown to predict coronary artery disease and it has been 
suggested that serum leptin is associated with increased production of C- reactive protein (39, 40, 
and 51). Although serum leptin has been linked to proinflammatory cytokines, the association of 
leptin with all-cause mortality and mortality from CVD was stronger after controlling for 





In addition to the current study, several previous studies have shown hyperleptinemia to 
be associated with the risk of T2D.  Elevated levels of serum leptin was associated with insulin 
resistance independent of total fat mass (84) and BMI (17) among women, while serum leptin 
formed a part of the cluster that constituted insulin resistance and hyperinsulinemia independent 
of measures of body fat (40 and 101). Recently, elevated leptin levels have been found to predict 
glucose intolerance in middle -aged white adults (45). Additionally Welsh et.al., in the PROSPER 
study found an independent association between risk of T2D  and serum leptin after adjusting for 
potential confounders and BMI (62). These studies, however, did not examine inflammatory 
markers, such as TNF-a, PAI-1, and IL-6 which have been shown to be related to the risk of type 
2 diabetes (89) and serum leptin (7),  
Several previous studies have also shown gender differences in the association of serum 
leptin and risk of T2D. Among women but not men, studies have shown that the association 
between serum leptin and insulin resistance are independent of total fat mass and BMI (17 and 
84). Furthermore, in a study among older men, the association of serum leptin with diabetes was 
mediated by obesity and insulin resistance (49 and 99). Women have been consistently shown to 
have higher serum leptin concentrations independent of total body fat mass or percent fat (85) and 
it has been proposed that elevated levels of serum leptin can lead to the development of leptin 
resistance (74) suggesting that women may be more leptin resistant as compared to men. Thus, 
the sex difference in the association of serum leptin with diabetes as a contributing cause of 
mortality in our study may be explained by relatively greater leptin resistance in women. 
  Several mechanisms have been postulated by which leptin exerts its direct (16) and 
indirect (14, 15, and 104) effect on the risk of T2D. It is suggested that leptin stimulates the 
oxidation of fatty acids, increases the uptake of glucose in muscle and liver by activating 5’ - 
Adenosine Mono Phosphate – activated Protein Kinase (AMPK) and thwarts lipotoxicity by 
preventing the spilling of fat to non-adipose tissue (14 and 104). Elevated levels of leptin may 




linked to impaired insulin action (14) and insulin resistance (15). Serum leptin directly affects the 
synthesis and release of insulin from pancreatic ß- cells and in turn, insulin stimulates secretion of 
leptin from adipose tissue creating a regulatory feedback loop, which is called adipoinsular axis 
(16). Leptin resistance in pancreatic ß - cells contributes to dysregulation of adipoinsular axis 
leading to hyperinsulinemia and T2D (16).  
In the current study, a significant interaction between leptin receptor (I/D) genotype 
and total percent fat was found among black women. The interaction term was inversely 
associated with diabetes as a contributing cause of mortality suggesting that total percent fat 
may modulate the association of leptin receptor I allele with diabetes as a contributing cause of 
mortality among black women independent of inflammatory factors. 
Several studies have examined the association between leptin receptor genotype and risk 
of T2D. Expression of leptin receptor gene in pancreatic beta-cells may lead to leptin-induced 
inhibition of insulin secretion (65). Thus, defect in leptin receptor gene may result in 
hyperinsulinemia due to leptin resistance (66). Lakka et al., and Nannipieri et al., reported lower 
serum insulin levels and risk of T2D among homozygous or heterozygous carriers of insertion 
allele than those who were homozygous for deletion allele (68 and 69). Although, Lakka et al., 
and Nannipieri et al., have reported protective effect of LEPR I/I and I/D genotype as compared 
to D/D genotype on diabetes risk (68 and 69), black women with LEPR I/I and I/D genotype were 
found to be at higher risk of diabetes as contributing cause of mortality after adjusting for total 
percent fat in our study. In the above studies, either combined analysis was performed on both 
genders (69) or the study sample included only men (68). The studies also lacked information on 
the race of the participants of the study (68 and 69). Thus, it is difficult to compare their finding 
with our results among black women. The racial difference observed in the association of leptin 
receptor (I/D) genotype with diabetes as a contributing cause of mortality, in the present study, 




possibly be explained by different linkage disequilibrium patterns or the different population 
histories of blacks and whites (147). 
Previous studies have shown the association between body leptin receptor genotype and 
body adiposity (71, 106, 126 and 127). Variants at 3’ region of leptin receptor gene have been 
associated with obesity in Pima Indians (127). In a study on overweight postmenopausal women, 
leptin receptor gene polymorphisms were shown to be associated with abdominal fat (71), while 
variations in DNA sequence in the leptin receptor gene was suggested to play a role in body fat 
distribution (71). Individuals with leptin receptor (I/I) (I/D) genotype had lower body weight than 
those with leptin receptor (D/D) genotype during 3 year follow up among impaired glucose 
tolerant individuals in Finnish Diabetes Prevention Study (126) and in STOP-NIDDM study 
(106), suggesting the potential role of this polymorphism in regulating body adiposity (106). 
However, in our sample of older adults, no difference was found in total percent fat and BMI 
among the two genotypes in white and black men and women. 
The protective effect of leptin receptor (I/I) (I/D) genotype on the risk of T2D has been 
reported frequently among obese subjects in the previous studies (67 and 128). Francke et al., 
reported that obese carriers of insertion allele have lower insulin concentrations compared with 
carriers of the D allele (128) and obese heterozygous women had lower insulin values at 30 
minutes in the oral glucose tolerance test (128). Additionally, better insulin sensitivity was found 
in obese subjects carrying the I allele because of lower insulin and insulin-to-glucose ratio (67). 
The protective effect of insertion allele in obese phenotype in the above studies (67 and 128) and 
interaction between leptin receptor (I/I) (I/D) and body fat in the present study on the risk of 
diabetes may imply that insertion allele lowers the risk of diabetes in presence of some amount of 
body fat, perhaps by reducing body weight (106 and 126). However, the reason behind the 
elevated risk of diabetes as a contributing cause of mortality in black women with (I/I) (I/D) 




The mechanism underlying the association between the 3’-UTR polymorphism and the 
risk of type 2 diabetes remains to be elucidated. A pentanucleotide insertion at 3’-UTR of LEPR 
generates a putative stem-loop motif in the leptin receptor mRNA (67). Stem-loop sequences 
affect mRNA stability by binding to the regulatory proteins, which in turn could affect the rate of 
degradation and/or translation of mRNA (148). However, there are no data on the direct effects of 
this polymorphism on leptin action or insulin secretion.  
Recently ethnic differences in the frequencies of leptin receptor Q223R (LEPRQ223R) 
genotype has been reported (149). The highest proportion of heterozygous variant was observed 
in African subjects, while Caucasian subjects had the lowest frequency of heterozygous variants 
(149). Because race was self reported in the present study, it is difficult to evaluate the admixture 
present in this population. Genetic admixture has been previously reported to lead to 
inappropriate classification of groups by genotype (150). Thus, the large study with complete 
epidemiological information and the frequencies of leptin receptor (I/D) genotypes on admixture 
is warranted. 
The strength of this study includes the longitudinal design of Health ABC study. Data 
were collected in several waves over a period of 10 years. HABC’s extensive information on life 
style and biochemical variables made it possible to control several potential confounders unlike 
previous studies. A limitation of this study is that there were not enough cases of mortality from 
cancer which did not permit us to examine the association between serum leptin and cancer 
mortality. This might have enabled us to provide a complete examination of the suggested U-
shape association between leptin and mortality from chronic conditions. Another limitation is the 
unavailability of data on other candidate leptin receptor genotypes for metabolic diseases among 
older adults such as Gln223Arg (134), which have been shown to be associated with serum 
insulin and obesity (71 and 151). 
In conclusion, the results of the present study suggest that although elevated levels of 




cause of mortality, moderately elevated leptin levels may protect from the risk of mortality from 
CVD among older women.  Because women are exposed to relatively elevated levels of leptin 
throughout their life, these effects of leptin were observed exclusively among women. The 
current finding of paradoxical association of leptin with cardiovascular risk factors and mortality 
from CVD would contribute to the understanding of pathophysiological implications that are 
elicited by hypo and hyperleptinemia in cardiovascular disease. Additionally, a significant 
interaction between leptin receptor genotype and body fat, if confirmed in functional study of 
genetic variants on admixture, may imply that leptin receptor genotype in relation to body 







Table 5.1 Baseline Characteristics of Men by Serum Leptin Quartile  1 
                                                                                                                     Serum Leptin Quartile                                                              
                                                                   1 2 3 4 
Men (n (%)) 354 (24.9) 355 (25) 355 (25) 355 (25) 
 
Mean Serum Leptin  (ng/ml) 3 2.11 (±0.93) 4.77 (±0.76) 2  7.92 (±1.13) 2  16.97 (±8.13)  2  
Demographic and behavioral variables 
Age (years) 3 75.4 (±2.9) 75.1 (±2.5) 75.4 (±3.0) 75.2 (±2.8) 
Race (% white) 62 67 692 56 
Drinking  (% any consumption) 64 60 55 532 
Education (% completed high school) 69 73 762 74 
Smoking (lifetime pack-years) 3 25.2 (±29.6) 25.2 (±29.5) 25.4 (±31.9) 27.1 (±31.1) 
Physical activity (kcal/kg/week)  3 9.35 (±20.6) 8.8 (±20.9) 7.7 (±17.1) 7.4 (±15.5) 
Dietary and anthropometric variables 
Total calorie intake (kcal) 4 2128 (±867) 2084 (±849) 1991 (±798) 1875 (±775) 
BMI (kg/m2) 3 23.75 (±2.7)  26.1 (±2.8)  2 28.1 (±2.9) 2  30.2 (±3.9)  2  
Total body fat (%)3 24.1 (±3.8) 28.2 (±3.0)  2  31.2 (±3.4)  2  33.3 (±4.2)  2  
Biochemical variables 
C-reactive protein (µg/ml) 3 2.44 (±4.3) 2.7 (±5.0) 2.7(±5.4) 2.8 (±3.1)   
IL-6 (pg/ml) 3 2.46 (±2.1) 2.27 (±1.62) 2.55 (±2.1) 2.6 (±1.8)   
TNF-alpha (pg/ml) 3 3.5 (±1.8) 3.5 (±2.1) 3.6 (±1.5) 3.9 (±1.9)  2 
Survival     
CVD mortality (%) 12.7 14.9 12.4 15.5 
T2D mortality (%) 9.94 9.01 11.3 18.92 
All-cause mortality (%) 43 39 352 40 
Genetic variable  
LEPR (I/D) or (I/I) genotype (%) 44 38 42 48 
1 Means (±SEM), unless otherwise specified. 
2 Significantly different from leptin quintile 1, P=0.05 (Dunnett’s test for continuous variables and chi-square test for categorical variables). 
3 Values from baseline of the Health ABC study 





Table 5.2 Baseline Characteristics of Women by Serum Leptin Quartile 1 
                                                                                                                 Serum Leptin Quartile                                                              
                                                                  1 2 3 4 
Women (n (%)) 375 (25) 375 (25) 375 (25) 375 (25) 





(±2.2) 2  
22.7 
(±2.9) 2  
 42.1 
(±11.1) 2  
Demographic and behavioral factors  
Age (years) 3 75.3 (±2.9) 75.3 (±2.9) 75.0 (±2.8)   75.0 (±2.8)   
Race (% white) 71 592 512 612 
Drinking  (% any consumption) 45 47 44 352 
Education (% completed high school) 84 78 772 702 
Smoking (lifetime pack-years) 3 14.2 (±25.2) 10.6 (±18.7) 13.4 (±25.6) 11.2 (±21.8) 
Physical activity (kcal/kg/week)  3 5.1 (±11.8) 4.6 (±10.3) 2.9 (±7.5)  2 3.9 (±15.6) 
Dietary and anthropometric variables 
Total calorie intake (kcal) 4 1731 (±627) 1717 (±684) 1701 (±657) 1677 (±629) 
BMI (kg/m2) 3 23.1 (±3.7)   26.4 (±3.9)  2 29.0 (±4.3)  2  32.3 (±4.9)  2  
Total body fat (%) 3 35.0 (±5.4)   39.5 (±3.9)  2  42.2 (±3.7)  2 45.0  (±4.1)  2 
Biochemical variables 
C-reactive protein (µg/ml) 3 2.6 (±5.6) 2.6 (±2.4) 3.7 (±4.6) 2 4.3 (±5.2)  2  
IL-6 (pg/ml) 3 2.0 (±1.8) 1.9 (±1.5) 2.5 (±2.1)  2 2.8 (±2.0)  2  
TNF-alpha (pg/ml) 3 3.3 (±1.6) 3.3 (±1.5) 3.3 (±1.3) 3.7 (±1.9)  2 
Survival 
CVD mortality (%) 11.7 9.6 9.3 10.4 
T2D mortality (%) 5.6 6.4 7.2 11.52 
All-cause mortality (%) 30 25 25 27 
Genetic variable  
LEPR (I/D) or (I/I) genotype (%) 39 41 37 45 
 
1 Means (±SEM), unless otherwise specified. 
2 Significantly different from leptin quintile 1, P=0.05 (Dunnett’s test for continuous variables and chi-square test for categorical variables). 
3 Values from baseline of the Health ABC study 





Table 5.3 Baseline Characteristics of Men by Race and Leptin Receptor Genotype 1  
 Whites Blacks  
 (D/D) (I/I) or (I/D) (D/D) (I/I) or (I/D)
Men (n (%)) 562 (62.4) 338 (37.5) 246 (47.3) 273 (52.6)
Mean Serum Leptin  (ng/ml) 3 7.75 (±0.29) 7.8 (± .36) 7.9 (± 0.29) 8.5 (± .36)
 
Demographic and behavioral variables 
Age (years) 3 75.2 (±0.1) 75.5 (±0.1) 75 (±0.1) 75.1 (±0.1)
Drinking  (% any consumption) 64 64.2 46 48
Education (% completed high school) 87 85 49 51
Smoking (lifetime pack-years) 3 27.1 (±1.4) 27.7(±1.8) 23.6 (±1.7) 22.3(±1.5)
Physical activity (kcal/kg/week) 3 11.0 (±.9) 9.2 (±.9) 5.1 (±1) 4.4 (±.9)
 
Anthropometric variables  
BMI (kg/m2) 3 27 (±.13) 26.8 (±.20) 27 (±.26) 27.3 (±.27)
Total body fat (%)3 30 (±0.2) 29.7 (±0.3) 28 (±0.3) 28.1 (±0.3)
 
Biochemical variables 
C-reactive protein (µg/ml) 3 2.7 (±.2) 1.94 (±.12)2 2.9 (±.3) 3.1 (±.2)
IL-6 (pg/ml) 3 2.4 (±.08) 2.3 (±.09) 2.5 (±.1) 2.7 (±.1)
TNF-alpha (pg/ml) 3 3.7 (±.08) 3.7 (±.09) 3.4 (±.2) 3.3 (±.1)
 
Survival 
CVD mortality (%) 13 12 16.3 16.5
T2D mortality (%) 7.8 9.5 18.3 18.3
All-cause mortality (%) 33 36 47 49
 
1 Means (±SEM), unless otherwise specified. 
2 Significantly different from leptin quintile 1, P=0.05 (t test for continuous variables and chi-square test 
for categorical variables). 





Table 5.4 Baseline Characteristics of Women by Race and Leptin Receptor Genotype 1  
 Whites Blacks  
 (D/D) (I/I) or (I/D) (D/D) (I/I) or (I/D)
Women (n (%)) 537 (65.5) 281 (34.3) 357 (52.3) 325 (47.6) 
Mean Serum Leptin  (ng/ml) 3 18.3 (± 0.6) 18.5 (± .8) 25 (± 0.8) 24.5 (± .8) 
 
Demographic and behavioral variables 
Age (years) 3 75.1 (±0.1) 75.3 (±0.2) 75 (±0.2) 75 (±0.2)
Drinking  (% any consumption) 56 442 34 27
Education (% completed high school) 90 89 65 59
Smoking (lifetime pack-years) 3 13.1 (±1.1) 12.7(±1.5) 12 (±1.1) 11 (±1.2)
Physical activity (kcal/kg/week) 3 5 (±.6) 7 (±.9) 2.4 (±.3) 2.5 (±.4) 
 
Anthropometric variables 
BMI (kg/m2) 3 26 (±.2) 26 (±.3) 30 (±.3) 29.5 (±.3)
Total body fat (%)3 40 (±0.2) 40.3(±0.3) 41 (±0.3) 40 (±0.3)
 
Biochemical variables 
C-reactive protein (µg/ml) 3 2.8 (±.2) 3.0 (±.3) 3.7 (±.3) 3.8 (±.3)
IL-6 (pg/ml) 3 2.2 (±.08) 2.0 (±.09) 2.6 (±.1) 2.6 (±.1)
TNF-alpha (pg/ml) 3 3.4 (±.06) 3.5 (±.1) 3.3 (±.1) 3.2 (±.1)
 
Survival 
CVD mortality (%) 9.3 7.8 11 13
T2D mortality (%) 3.9 4.2 9.5 14.82
All-cause mortality (%) 22 23 30 34
 
1 Means (±SEM), unless otherwise specified. 
2 Significantly different from leptin quintile 1, P=0.05 (t test for continuous variables and chi-square test 
for categorical variables). 





Table 5.5 Adjusted Relative Risk (RR) of All-Cause Mortality by Serum Leptin Quartile  
Serum Leptin Quartile    
  1 2 3 4 
p for 
logleptin1 
Men (n) 354 355 355 355   
Serum leptin quartile  









All-Cause mortality cases 
(n) 151 139 125 141 0.241 
Model 1  
RR  
(95% CI) 1 
0.97  
(0.76 - 1.23) 
0.79  
(0.61 - 1.01) 
0.88  
(0.69 - 1.12) 0.44 
Model 2 
RR  
(95% CI) 1 
1.04  
(0.79 - 1.37) 
0.85  
(0.62 - 1.17) 
1.03  
(0.72 - 1.46) 0.30 
Model 3 
RR  
(95% CI) 1 
0.93  
(0.70 - 1.23) 
0.74  
(0.53 - 1.03) 
0.82  
(0.56 - 1.94) 0.06 
 
Women (n) 375 375 375 375   
Serum leptin quartile  






 (± 2.91) 
42.13 
 (± 11.17) <0.0001 
All-Cause mortality cases 
(n) 111 92 95 103 0.0003 
Model 1   
RR  
(95% CI) 1 
 0.71  
(0.53 - 0.95) 
0.73  
(0.55 - 0.98) 
0.84  
(0.63 - 1.13) 0.50 
Model 2  
RR  
(95% CI) 1 
0.78  
(0.56 - 1.09) 
0.82  
(0.58 - 1.17) 
1.06  
(0.71 - 1.58) 0. 25 
Model 3 
RR  
(95% CI) 1 
0.72 
 (0.51 - 
1.02) 
0.68  
(0.47 - 0.99) 
0.76  
(0.50 - 1.67) 0.89 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, and physical activity 
(total calorie intake, hormonal replacement therapy and numbers of hours fasted were not significant 
and did not affect the association between predictor and outcome, so they were not included in the 
model) 
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity and 
TOTPF 
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, 





Table 5.6 Adjusted Relative Risk (RR) of CVD Mortality by Serum Leptin Quartile  
                                                                                   Serum Leptin Quartile                                                               
  1 2 3 4 
p for 
logleptin1 
Men (n) 354 355 355 355   
Serum leptin quartile 









CVD mortality cases 
(n) 45 53 44 55 0.48 
Model 1  
RR  
(95% CI) 1 
1.96  
(0.79 -  1.83) 
0.99  
(0.64 - 1.53) 
1.09  
(0.71 - 1.67) 0.21 
Model 2 
RR  
(95% CI) 1 
1.16 
 (0.69 - 1.78) 
0.88  
(0.51 - 1.50) 
0.70  
(0.49 - 1.38) 0.24 
Model 3 
RR  
(95% CI) 1 
0.99  
(0.61 - 1.60) 
0.71  
(0.40 - 1.23) 
0.67  
(0.35 - 1.27) 0.14 
 
Women (n) 375 375 375 375   
Serum leptin quartile  








 (± 11.17) <0.0001 
CVD mortality cases 
(n) 44 36 35 39 0.543 
Model 1  
RR  
(95% CI) 1 
 0.60  
(0.37 - 0.97) 
0.71  
(0.45 - 1.25) 
0.76  
(0.48 - 1.21) 0.71 
Model 2  
RR  
(95% CI) 1 
0.64  
(0.38 - 1.11) 
0.77  
(0.43 - 1.35) 
0.97  
(0.51 - 1.85) 0.26 
Model 3 
RR  
(95% CI) 1 
0.48  
(0.27 - 0.86) 
0.50  
(0.27 - 0.92) 
0.59  
(0.29 - 1.19) 0.85 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, and physical activity 
(total calorie intake, hormonal replacement therapy and numbers of hours fasted were not significant 
and did not affect the association between predictor and outcome, so they were not included in the 
model) 
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity and 
TOTPF 
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, 





Table 5.7 Adjusted Relative Risk (RR) of Diabetes as a Contributing Cause of Mortality by 
Serum Leptin Quartile  
                                                                                   Serum Leptin Quartile                                                                   
  1 2 3 4 
p for 
logleptin 1 
Men (n) 354 355 355 355   
Serum leptin quartile 









T2D mortality cases (n) 32 32 40 67 0.48 
 
Model 1  
RR  
(95% CI) 1 
0.99  
(0.59 - 1.67) 
1.26  
(0.78 - 2.06) 
2.07  
(1.33 - 3.25) 0.0006 
 
Model 2  
RR  
(95% CI) 1 
1.18  
(0.67 - 2.09) 
1.57  
(0.86 - 2.85) 
2.79  
(1.49 - 5.25) 0.0003 
 
Model 3  
RR (95% CI) 1 
0.55  
(0.27 - 1.14) 
0.84  
(0.45 - 1.58) 
0.94  
(0.51 - 1.73) 0.19 
Women (n) 375 375 375 375   
Serum leptin quartile  








(± 11.17) <0.0001 
T2D mortality cases (n) 21 24 27 43 0.484 
 
Model 1   
RR  
(95% CI) 1 
0.82  




(0.84 - 2.55) 0.01 
 
Model 2   
RR  
(95% CI) 1 
1.01  
(0.49 - 2. 08) 
1.16  
(0.55 - 2.44) 
2.42  
(1.09 - 5.35) 0.0006 
 
Model 3  
RR  
(95% CI) 1 
1.03  
(0.49 - 2.17) 
0.90  
(0.41 - 2.01) 
1.56  
(0.67 - 3.60) 0.02 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, and physical activity 
(total calorie intake, hormonal replacement therapy and numbers of hours fasted were not significant 
and did not affect the association between predictor and outcome, so they were not included in the 
model) 
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity and 
TOTPF 
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, 





Table 5.8 Adjusted Relative Risk (RR) of Diabetes as a Contributing Cause of Mortality by 
Leptin Receptor Polymorphism and Race Among Men 
                                                                                   Leptin Receptor (I/D)                                                                
  (D/D) (I/D) or (I/I) p value  
White Men (n) 562 338 <0.0001 
T2D mortality cases (n) 44 32  
Model 1     
RR (95% CI) 1 1.25 (0.78 - 2.0) 0.36 
Model 2    
RR (95% CI) 1 1.28 (0.79 - 2.1) 0.31 
Model 3 (model 2 + totpf*lepr2id)    
RR (95% CI) 1 1.01 (0.91 - 1.12) 0.79 
Model 4 (Model3 + inflammation)    
RR (95% CI) 1 1.03 (0.92 - 1.17) 0.52 
Black Men (n) 246 273 <0.0001 
T2D mortality cases (n) 45 50  
Model 1     
RR (95% CI) 1 0.97 (0.64 - 1.47) 0.88 
Model 2     
RR (95% CI) 1  0.97 (0.64 - 1.49) 0.89 
Model 3 (model 2 + totpf*lepr2id)    
RR (95% CI) 1 0.95 (0.87 - 1.03)  0.21 
Model 4 (Model3 + inflammation)    
RR (95% CI) 1 0.91 (0.89 - 1.01) 0.05 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, and physical activity 
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, and 
TOTPF 
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, and 
TOTPF*LEPR2ID  
Model 4: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, 






Table 5.9 Adjusted Relative Risk (RR) of Diabetes as a Contributing Cause of Mortality by 
Leptin Receptor Polymorphism and Race Among Women 
                                                                                   Leptin Receptor (I/D)                                                                
  (D/D) (I/D) or (I/I) p value  
White Women (n) 537 281 <0.0001 
T2D mortality cases (n) 21 12  
Model 1     
RR (95% CI) 1 1.17 (0.57 - 2.39) 0.66 
Model 2    
RR (95% CI) 1 1.01 (0.47 - 2.15) 0.98 
Model 3 (Model2 + totpf*lepr2id)    
RR (95% CI) 1 0.98 (0.86 - 1.12) 0.81 
Model 4 (Model3 + inflammation)    
RR (95% CI) 1 1.06 (0.91 - 1.22) 0.46 
Black Women (n) 357 325 <0.0001 
T2D mortality cases (n) 34 48  
Model 1     
RR (95% CI) 1 1.25 (0.78 - 2.0) 0.36 
Model 2     
RR (95% CI) 1 1.64 (1.01 - 2.68) 0.046 
Model 3 (model 2 + totpf*lepr2id)    
RR (95% CI) 1 0.86 (0.79 - 0.94) 0.001 
Model 4 (Model3 + inflammation)    
RR (95% CI) 1 0.87 (0.79 - 0.95) 0.003 
 
1: Tests for linear trend used leptin as a continuous variable in logistic regression. 
Model 1: Adjusted by age, race, site, years of education, alcohol use, smoking, and physical activity 
Model 2: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, and 
TOTPF 
Model 3: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity, and 
TOTPF*LEPR2ID  
 Model 4: Adjusted by age, race, site, years of education, alcohol use, smoking, physical activity,  




Chapter 6: Serum Leptin Cut Off Level Suggesting Risk of 
Metabolic Syndrome Among Older Adults 
 
Abstract 
Background: Serum leptin is suggested as an independent risk factor for coronary 
heart disease. Elevated levels of serum leptin are associated with insulin resistance and increased 
risk of metabolic syndrome independent of measures of adiposity.  
Objectives: The objective of the present study was to determine the serum leptin cut 
off level that predicts the risk of metabolic syndrome among older men and women. A secondary 
aim was to compute and compare the cut off values of serum leptin, serum leptin per kilogram of 
body fat and serum leptin per unit of BMI for determining incidence of metabolic syndrome at 
year 6. 
Design:  The Health, Aging and Body Composition (HABC) study is a prospective 
cohort of 3,075 older adults aged 70 to 79 years. Metabolic syndrome at year 6 was defined by 
the NCEP ATPIII definition as presence of 3 or more of the 5 risk components as follows: 1) 
waist circumference >102 cm for men and >88 cm for women; 2) triglyceride (TG) =150 mg/dl; 
3) high-density lipoprotein cholesterol (HDL-C) <40 mg/dl for men and <50 mg/dl for women; 4) 
blood pressure (BP) = 130/85 mmHg or currently on antihypertensive medicine(s); 5) fasting 
glucose =110 mg/dl or currently using anti-diabetic (insulin or oral agents) medication. 
Anthropometric measures were evaluated in detail. 
Results: The serum leptin cut off value for diagnosis of metabolic syndrome was 6.45 




and 62% specificity among women. The area under curve (AUC) was 0.62 for serum leptin, 0.58 
for leptin per kilogram of body fat, and 0.59 for leptin per unit of BMI among men and women.  
Conclusion: The prediction of metabolic syndrome was better by serum leptin as 
compared to leptin per kilogram of body fat and leptin per unit of BMI among older adults. The 
serum leptin cut off value may be included among risk factors of metabolic syndrome for 
identifying people at risk.  
 
Introduction 
Leptin is an adipocyte derived polypeptide hormone that influences feeding behavior 
through its direct effect on the hypothalamus (6). Serum levels of leptin reflect the amount of 
energy stored in adipose tissues (7). Previous studies have reported that serum leptin levels 
decrease with aging and that older adults have lower levels of circulating leptin as compared to 
younger adults (9, 38, and 76). However, recent studies refuted these previous findings and 
demonstrated that aging is accompanied by increase in serum leptin levels (36 and 37). A 
concomitant increase in serum leptin and TNF- a with aging has been associated with obesity and 
atherosclerosis (7 and 38). 
Leptin plays a critical role in the inflammatory response (35) and has been implicated 
in the etiology of insulin resistance (40) and metabolic syndrome (76, 40, and 49). Leptin directly 
inhibits insulin secretion from pancreatic ß- cells (46) and elevated serum leptin levels are shown 
to be associated with fasting insulin, insulin resistance (HOMA-IR), and total cholesterol (40, 42, 
43, 45 and 140), that are the core metabolic disturbances of the metabolic syndrome (141). It has 
been also demonstrated by elegant experiments on rodent models that failure of leptin to “cross 
talk” with other fat depots to regulate fat distribution has a cause-effect relationship between the 
age-related increase in visceral fat and the decrease in hepatic insulin action (44), which are major 




Although serum leptin levels have been consistently shown to be associated with 
metabolic syndrome and its components, none of the studies have determined the serum leptin cut 
off level that suggests the risk of metabolic syndrome among older adults. 
The primary objective of this study was to find out the serum leptin cut off value that 
suggests the risk of metabolic syndrome among older men and women. In addition, the other 
objective was to compute and compare the performance of cut off points for serum leptin, leptin 
per kilogram of body fat and leptin per unit of BMI.   
 
 
Subjects and Methods  
Study Design 
The Health, Aging and Body Composition (Health ABC) study is a longitudinal 
cohort study of 3,075 community dwelling, well functioning white and black men and women 
aged 70 to 79 years at the commencement of the study. Participants were recruited for the study 
from a random sample of white residents receiving Medicare benefits and from all age-eligible 
black residents of Pittsburgh, Pennsylvania, and Memphis, Tennessee. Subjects were considered 
eligible to participate in the study if they reported no difficulty walking a quarter of a mile, 
climbing 10 steps without resting, or performing basic activities of daily living, were free of life-
threatening illness, and planned to remain in the geographic area for at least 3 years. Those who 
reported active treatment for cancer or participation in diet or exercise intervention were excluded 
from the study. Participants gave written informed consent, and protocols were approved by the 
Institutional Review Boards at the two study sites.  A home interview was administered to 
participants to collect information on demographic, socioeconomic factors and health behaviors 
between April 1997 and June 1998. A clinic visit was conducted for examination of biochemical 








In the present study, data from baseline and year 6 of the Health ABC study were 
used. The data of individuals with prevalent metabolic syndrome at baseline (n = 768) and at year 
6 (n=143) were excluded from the analysis. Also excluded were the data of individuals with 
missing or implausible values for leptin (n = 180) and total body fat (n = 775). 
 
Biochemical Variables 
Participants underwent venipuncture at baseline visit after an overnight fast, and 
serum samples were frozen at -70°C. Plasma glucose was measured using an automated glucose 
oxidase reaction (YSI 2300 Glucose Analyzer; Yellow Springs Instruments, Yellow Springs, 
OH). Triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) were measured using a 
chemical analyzer (Vitros 950; Johnson & Johnson, Raritan, NJ). Serum concentrations of leptin 
were measured in duplicate by means of radioimmunoassay (Linco Research Inc, St Charles, 
Mo). The assay range is 0.05 to 100 ng/ml leptin in serum or plasma. Intraassay coefficient of 
variations (CVs) ranged from 3.7% to 7.5%, and interassay CVs ranged from 3.2% to 8.9%. The 
assay is highly specific for human leptin and shows minimal reactivity with mouse or rat leptin 
(91). 
 
Anthropometric and Clinical Variables 
Weight was measured using a standard balance beam scale in kilograms. Height was 
measured twice using a Harpenden stadiometer (Holtain Ltd., Crosswell, U.K.) in centimeters and 
the average of the two measurements was used. Body mass index (BMI) [weight (kg)/height 




version 8.21, Hologic, Waltham, MA) was used to assess the total fat mass (77). Systolic and 
diastolic blood pressures were measured by manual sphygmomanometer in a seated position on 
left arm. 
 
Demographic and Life Style Variables 
A standardized questionnaire was administered at baseline to collect information on 
socio-demographic variables including age, gender, race and years of education, and; on lifestyle 
variables including smoking status and average alcohol consumption during the past year (0, 1-2 
or >2 drinks/day). Cigarettes smoked per day were multiplied by the number of years of smoking 
to calculate the pack-years over a lifetime of cigarette smoking. Level of physical activity was 
obtained using a standardized questionnaire specifically designed for the Health ABC study. The 
frequency, duration, and intensity level of activities were recorded, and the approximate values of 
metabolic equivalent unit (MET) were assigned to each activity category to estimate weekly 
energy expenditure in kcal/kg/week (78). 
 
Outcome Variable  
In Health ABC, metabolic syndrome at year 6, was defined according to the National 
Cholesterol Education Program, Adult Treatment Panel III (NCEP ATP III) as the presence of 3 
or more of the 5 risk components as follows: 1) waist circumference >102 cm for men and >88 
cm for women; 2) TG =150 mg/dl; 3) HDL-C <40 mg/dl for men and <50 mg/dl for women; 4) 
blood pressure (BP) = 130/85 mmHg or currently on antihypertensive medicine(s); 5) fasting 
glucose =110 mg/dl or currently using anti-diabetic (insulin or oral agents) medication. 
 
Statistical analysis 
Multivariate logistic regression analysis was used to assess the association of serum 




at year 6 after adjustment for potential confounders (age, race, site, and years of education, 
alcohol use, smoking, and physical activity) in both genders. Serum leptin values and body fat 
vary by gender, therefore, the cut off value of serum leptin levels were determined separately by 
gender. Receiver operating characteristic (ROC) curve was used to find out the serum leptin cut 
off value for determining risk of metabolic syndrome. The “gold standard” for the ROC curves 
was based on the presence of metabolic syndrome at year 6.  Sensitivity and specificity were 
calculated for several cut off points of serum leptin among men and women. Because serum 
leptin has been shown to be associated with total body fat, sensitivity and specificity of the cut off 
values of serum leptin per kilogram of body fat and serum leptin per unit of BMI were also 
computed for determining the risk of metabolic syndrome at year 6. To evaluate the cut off point 
for the above three tests, the shortest distance on the sex-specific ROC curve was computed and 
searched. A distance on the ROC curve is equal to v (1-sensitivity)2 + (1-specificity)2 (43). 
Younden index (J) was also calculated for all three tests. Youden index is defined as sensitivity 
plus specificity minus 1. When the test is perfect J is 1, while its equal to 0 when the performance 
of test is poor. The value with shortest distance and highest J was selected as the cut off point. 
Area under curve (AUC) was estimated by logistic regression analysis and the test with highest 
AUC was considered to be the best among three tests for determining risk of metabolic syndrome. 
Statistical significance was set at p = 0.05, and analyses performed using SAS (version 9.1; SAS 






There was a significant difference (p<0.0001) between the mean serum leptin 
concentrations among men (7.1 ±5.8) ng/ml) and women (18.7 ±13.3 ng/ml). Baseline 
characteristics indicate that among men (leptin cut off value = 6.45 ng/ml) and women (leptin cut 
off value = 18.25 ng/ml), those with serum leptin levels below the cut off point had significantly 
lower, BMI, abdominal circumference, total fat mass, abdominal visceral fat, subcutaneous fat, 
and triglycerides as compared to those with serum leptin levels above the cut off point. 
Additionally, men with serum leptin levels below the cut off value had significantly lower 
diastolic blood pressure and women with serum leptin levels below the cut off value had 
significantly lower fasting glucose and HDL cholesterol as compared to men and women with 
serum leptin levels above the cut off point. Women with serum leptin levels below the cut off 
point were more likely to be white, complete high school and were older as compared to those 
with serum leptin levels above the cut off point (Table 6.1 and 6.2). 
In multivariate analysis, serum leptin and serum leptin per unit of BMI were 
significantly associated with the risk of developing metabolic syndrome after adjusting for 
potential confounders among men (1.71; 95% CI = 1.26 – 2.32), (OR = 1.58; 95% CI = 1.14 – 
2.2), respectively. Among women, serum leptin (OR = 2.02; 95% CI = 1.49 – 2.74), serum leptin 
per kg of body fat (OR = 1.89; 95% CI = 1.3 – 2.75), and serum leptin per unit of BMI (OR = 
1.98; 95% CI = 1.4 –2.8) were positively associated with increased risk of developing metabolic 
syndrome after adjusting for potential confounders   (Table 6.3). 
Among men, area under ROC curve (AUC) for serum leptin was higher (0.62) as 
compared to AUC of 0.58 and 0.59 for serum leptin per kg of body fat and serum leptin per unit 
of BMI, respectively. The serum leptin cut off values for determining metabolic syndrome was 
found to be 6.45 ng/ml with shortest distance on ROC curve, highest Youden’s index (J) of 0.23 
and sensitivity and specificity of 60% and 63 %, respectively. The cut off points for serum leptin 




0.27 ng/ml per kg body fat and 0.22 ng/ml per unit of BMI were found to predict metabolic 
syndrome risk with sensitivity of 54% and 65%, respectively and specificity of 60% and 55%, 
respectively. The appropriate value of J for leptin per kg body fat and leptin per unit of BMI were 
0.14 and 0.20, respectively (Table 6.4). The ROC curve for serum leptin concentrations 
predicting metabolic syndrome among men is shown in Figure 6.1. 
Among women, area under ROC curve (AUC) for serum leptin was higher (0.62) as 
compared to AUC of 0.58 and 0.59 for serum leptin per kg of body fat and serum leptin per unit 
of BMI, respectively.  The serum leptin cut off values for predicting metabolic syndrome was 
found to be 18.25 ng/ml with shortest distance on ROC curve, highest Youden’s index (J) of 0.17 
and a sensitivity and specificity of 55% and 62 %, respectively. Serum leptin level of 0.61 ng/ml 
per kg body fat and 0.71 ng/ml per unit of BMI were found to predict metabolic syndrome risk 
with sensitivity of 61% and 51%, respectively and specificity of 54% and 65%, respectively. The 
appropriate value of J for leptin per kg body fat and leptin per unit of BMI were 0.15 and 0.16, 
respectively (Table 6.4). The ROC curve for serum leptin predicting metabolic syndrome among 






In the present study, compared to men, women had higher serum leptin concentrations 
and cut off values for the three tests (18.25 ng/ml for leptin, 0.61 ng/ml for leptin per kg body fat, 
and 0.71 ng/ml for leptin per unit of BMI among women; 6.45 ng/ml for leptin, 0.27 ng/ml for 
leptin per kg body fat, and 0.22 ng/ml for leptin per unit of BMI among men). Serum leptin had 
the highest Youden’s index (J), AUC and sensitivity and specificity in association with the risk of 
metabolic syndrome as compared to serum leptin per unit body fat and serum leptin per unit of 
BMI, among men and women.  
Few longitudinal (40 and 79) and several cross-sectional (17, 18, 19, 40, 42, 81, and 
125) studies have shown a significant association between serum leptin concentrations, the 
metabolic syndrome and its components. Franks et al., in the Medical Research Council Ely 
Study of subjects aged 50-59 years, found leptin to be positively rela ted to the risk of metabolic 
syndrome after adjusting for obesity (79).  In men aged 45±1.3 years, when risk factors of the 
metabolic syndrome were considered together in factor analysis, serum leptin formed a part of the 
cluster that constituted insulin resistance and hyperinsulinemia independent of measures of body 
fat (40). In addition, serum leptin has been shown to be positively associated with systolic blood 
pressure among women and with diastolic blood pressure among men (81). Hyperleptinemia was 
positively associated with serum insulin levels while a negative association has been reported 
between serum leptin and triglyceride levels (17, 19, 40, 81, and 125). Recently Zhuo et al., in a 
cross-sectional study on Chinese older population, showed that association of leptin to 
adiponectin ratio and leptin alone with metabolic syndrome was stronger than adiponectin alone 
after adjusting for BMI (132), while Kumagai et al., in glucose intolerant and diabetic subjects 
found that relationship of leptin to adiponectin ratio, leptin and adiponectin alone with metabolic 
syndrome is dependent on abdominal adiposity and cardio-respiratory fitness (131). Although 




components of metabolic syndrome, none of them have determined a cut off value of serum leptin 
for determining the risk of metabolic syndrome.  
Previous studies have consistently shown a correlation between circulating levels of 
leptin and variables of body adiposity, such as BMI, percent body fat and total fat mass (48, 88, 
115, and 116). BMI and waist circumference were found to be the strongest determinants of 
serum leptin levels among middle aged women and men, respectively (48), while percent body fat 
was shown to be the best adiposity-related predictor of serum leptin among post menopausal 
women (116). Recently, the adipocyte was recognized as an endocrine organ that plays a 
prominent role in metabolic disorders (114). Leptin per kg of fat mass is an indicator of adipocyte 
function (117), and BMI have been shown to be a good indicator of body fat (115). Thus, the cut 
off values for both, serum leptin per kg of body fat and serum leptin per unit of BMI, were 
identified in the present study.  
Although serum leptin has been shown to be related to body adiposity, several studies 
have shown an independent association between serum leptin and metabolic diseases (40, 79, and 
83). The Atherosclerosis Risk in Communities (ARIC) study showed an independent association 
between elevated leptin and diabetes after adjusting for potential confounders and adiposity 
among both men and women (45). A recent study from National Health and Nutrition 
Examination Survey (NHANES) found a positive association between higher serum leptin and 
myocardial infarction or stroke independent of obesity (86). Similarly, a study on type 2 diabetic 
men showed a concomitant increase in the serum leptin and insulin resistance independent of 
body adiposity (124). Thus, higher predictive value of serum leptin levels (shown by higher AUC 
and J value for serum leptin) as compared to serum leptin per kg of body fat and serum leptin per 
unit of BMI supports the adiposity independent association between serum leptin and metabolic 
syndrome found in the above studies. The AUC for the prediction of metabolic syndrome by 
serum leptin levels (~0.62) was significantly higher than what would be expected by chance, 




of AUC (1.0 for perfect prediction), these AUC values suggested that other risk factors also 
contributed to the prediction of metabolic syndrome. Therefore, it may be useful to include serum 
leptin cut off values among other risk factors of metabolic syndrome. 
 Several previous studies have shown higher serum leptin concentrations among 
women as compared to men (72, 85, and 86). There is a concomitant increase in serum leptin and 
body fat among men and women (88, 115 and 116). But, for any given measure of obesity, serum 
leptin levels are higher in women than men because of relative hyperleptinemia among women 
(88 and 115). Thus, to achieve similar biological effect, higher levels of serum leptin are required 
among women (115), which may explain our finding of the relatively higher cut off values among 
women. 
In the current study, the sensitivities and specificities of the cut off points for all the 
three tests were moderate. Several studies have shown that a subject’s clinical and pathological 
characteristics may lead to the variation in sensitivity and specificity of the diagnostic test (118, 
119 and 122). Leeflang et al., with a series of examples, demonstrated that prevalence of a disease 
is a marker of variations in the sensitivity and specificity in different clinical populations (123). 
Studies that were performed on a population with higher disease prevalence or disease severity 
have shown higher sensitivity and specificity (120, 121 and 122). Thus, the low prevalence of 
metabolic syndrome (21.7 % in women and 19 % in men) in our study population of well-
functioning older adults may explain the moderate sensitivities and specificities of the three cut 
off values in the present study.   
The strength of this study includes the use of longitudinal data for determining the cut- 
off value of serum leptin. The HABC study collected extensive information on life style and 
anthropometric variables, which made it possible to adjust for many potential confounders in the 
multivariate analysis. A limitation of this study is that the sensitivities and specificities of the cut 




the Health ABC study cohort. Future studies on older population with higher prevalence of 
metabolic syndrome are needed to confirm the diagnostic value of serum leptin. 
In conclusion, the current study suggests that serum leptin value of 6.45ng/ml in men and 
18.25 ng/ml in women may be cut- off values for determining the risk of metabolic syndrome 
among older adults. Measurement of body fat mass requires expensive and invasive techniques 
(88), limiting its use in large population studies. BMI has been shown to be a good indicator of 
percent body fat (88), but a natural decease in height among older adults may lead to the 
overestimation in the number of overweight older adults (133). Serum leptin is relatively reliable 
and feasible to measure and has been shown to be predictive of metabolic syndrome risk (40 
and79).  Thus, the inclusion of serum leptin among the other risk factors of metabolic syndrome 
may improve the diagnosis of individuals at risk of chronic disease and may play an important 





Tables and Figures: 
Table 6.1 Baseline Characteristics of Men by Serum Leptin cutoff value1 
 Leptin =6.45 (ng/ml) Leptin >6.45 (ng/ml) 
Men (n (%)) 343 (58) 251 (42)  
Mean Serum Leptin (ng/ml) 3 3.7 (± 0.8)   11.6 (± 0.39) 2 
 
Demographic and behavioral variables 
Age (years) 3 75.2 (±0.15) 75.2 (±0.18) 
Race  (% white) 69 63 
Drinking (% any consumption) 65 61 
Education (% completed high school) 76 78 
Smoking (lifetime pack-years) 3  19.9 (±1.36) 22.8 (±1.94)  
Physical activity (kcal/kg/week) 3 10 (±1.2) 9.9 (±17.8) 
 
Anthropometric variables 
BMI (kg/m2) 3 25 (±0.13) 29 (±0.21) 2 
Abdominal circumference (cm) 3 95 (±0.45) 103 (±0.55)  2 
Abdominal visceral fat (cm2) 3 123 (±2.6) 167 (±4.2) 2 
Abdominal subcutaneous fat (cm2) 3 181 (±2.8) 262 (±4.7) 2 
Total body fat mass (kg)  3 20 (±0.21) 27 (±0.38) 2 
 
Biochemical and clinical variables 
Diastolic Blood pressure (mmHg) 3 71 (±0.63) 74 (±0.73) 2 
Systolic Blood pressure (mmHg)  3 132 (±1.05) 135 (±1.32) 
Fasting glucose (mg/dl) 3 97 (±1.4) 99 (±1.4) 
HDL cholesterol (mg/dl) 3 51 (±0.71) 50 (±0.67)  
Triglycerides (mg/dl) 3 106 (±2.2) 115 (±2.9) 2 
 
1 Means (±SEM), unless otherwise specified. 
2 Significant difference between the two groups 1, P=0.05 (t test for continuous variables and chi-square 
test for categorical variables).. 





Table 6.2 Baseline Characteristics of Women by Serum Leptin cutoff value 1  
 
1 Means (±SEM), unless otherwise specified. 
2 Significant difference between the two groups, P=0.05 (t test for continuous variables and chi-square 
test for categorical variables). 
3 Values from baseline of the Health ABC study 
  Leptin =18.25 (ng/ml) Leptin >18.25 (ng/ml) 
Women (n (%)) 358 (58.2) 257 (41.8)  
Mean Serum Leptin (ng/ml) 3 9.7 (± 0.15)   31.4 (± 0.45) 2 
 
Demographic and behavioral variables 
Age (years) 3 75.3 (±0.11) 74.7 (±0.09) 2  
Race  (% white) 74 422 
Drinking (% any consumption) 48 43 
Education (% completed high school) 84 752 
Smoking (lifetime pack-years) 3 12.3 (±0.84) 12.03 (±0.81)   
Physical activity (kcal/kg/week)  3 4.9 (±0.44) 3.5 (±0.41)   
 
Anthropometric variables 
BMI (kg/m2) 3 24.5 (±0.15) 30.4 (±0.17)2 
Abdominal circumference (cm) 3 91.1(±0.41) 105.2 (±0.43)  2 
Abdominal visceral fat (cm2) 3 108 (±2.05) 151 (±2.03)  2 
Abdominal subcutaneous fat (cm2) 3 266 (±3.52) 401 (±3.99)2 
Total body mass(kg) 3 23 (±0.34) 33 (±0.46)2 
 
Biochemical and clinical variables 
Diastolic Blood pressure (mmHg) 3 70 (±0.45) 70.4 (±0.41) 
Systolic Blood pressure (mmHg) 3 136 (±0.77) 137 (±0.76) 
Fasting glucose (mg/dl) 3 98 (±1.2) 105 (±1.22)2  
HDL cholesterol (mg/dl) 3 62 (±0.69) 59 (±0.57)2 




Table 6.3 Adjusted Odd Ratios (OR) of Metabolic Syndrome at Year 6 by Serum Leptin, 
Leptin per kg Body Fat Mass, and Leptin per unit of BMI Among Men and Women  
  Serum Leptin Leptin/ kg Fat 
Mass 
 Leptin / BMI 
Men (n) 479 479 479 
Metabolic Syndrome Cases (n) 115 115 115 
OR (95% CI) 1.71 (1.26 – 2.32) 1.42 (0.99 – 2.1) 1.58 (1.14 – 
2.2) 
Women (n) 481 481 481 
Metabolic Syndrome Cases (n) 134 134 134 
OR (95% CI) 2.02 (1.49 – 2.74) 1.89 (1.3 – 2.75) 1.98 (1.4 – 2.8) 




Table 6.4 Comparison of Optimal Value, AUC, Sensitivity, Specificity, and Youden’s 
Index (J) of Leptin, Leptin per kg Body Fat Mass, and Leptin per unit of BMI for 




Cutoff AUC Sensitivity Specificity J 
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Chapter 7:  Summary and Implications 
 
A. Summary  
In this study the prospective association of serum leptin with risk of metabolic 
syndrome, all-cause mortality and morta lity from CVD was examined. Association between 
serum leptin and diabetes as a contributing cause of death and leptin receptor (I/D) genotype 
was also investigated. The influence of proinflammatory cytokines and markers of adiposity 
on these associations were explored. In addition, cut off values of serum leptin, leptin per kg 
of body fat and leptin per unit of BMI for determining risk of metabolic syndrome were 
identified. 
Women were found to have significantly higher serum leptin levels as compared to 
men. Men and women in quintile 1 of serum leptin had significantly lower BMI, abdominal 
visceral fat, abdominal subcutaneous fat and total fat percent as compared to men and women 
in all other quintiles. Additionally, individuals in quintile 1 had significantly lower C- reactive 
protein and PAI-1 than those in quintile 4 and 5.  Women in quintile 1 of serum leptin were 
found to be at significantly lower risk of developing metabolic syndrome at year 6 than 
women in all other quintiles. The positive association of serum leptin with metabolic 
syndrome was independent of proinflammatory cytokines and body adiposity among women. 
In contrast to the results in women, the association between serum leptin and metabolic 
syndrome was dependent on body adiposity among men.  
Women in intermediate levels of serum leptin were at lower risk of all-cause 
mortality and mortality from CVD as compared to those with low levels of leptin after 
adjusting for body fat and proinflammatory cytokine. Additionally, women with elevated 




Among men, no association was found between serum leptin and all-cause mortality and 
mortality from CVD, while the association between leptin and risk for diabetes as a 
contributing cause of death was explained by proinflammatory cytokines among men.  
An interaction was found between leptin receptor (I/D) genotype and total percent 
fat in relation to risk of diabetes as a contributing cause of death among black women. White 
men who were homozygous for deletion allele at the 3’UTR region of leptin receptor gene had 
higher C- reactive protein as compared to those who were heterozygous or homozygous for 
insertion allele. Black women who were homozygous for deletion allele had significantly 
lower risk of diabetes as a contributing cause of mortality as compared to those who were 
heterozygous or homozygous for insertion allele.  
Cut off values of serum leptin, leptin per kg of body fat and leptin per unit of BMI 
were found to be 18.25 ng/ml, 0.61 ng/ml, and 0.71 ng/ml, respectively, among women.  
Among men, the cut off values of serum leptin, leptin per kg of body fat and leptin per unit of 
BMI were found to be 6.45 ng/ml, 0.27 ng/ml, and 0.22 ng/ml, respectively. The area under 
curve (AUC), Youden Index (J) and sensitivities and specificities were highest for serum 
leptin in identifying risk of metabolic syndrome compared to serum leptin per unit of body fat 
mass and serum leptin per unit of BMI among men and women. Men and women with serum 
leptin values below the cut off point had significantly lower BMI, total fat mass, abdominal 
visceral and subcutaneous fat than those with serum leptin concentrations above the cut off 
point.  
Direct comparison of the results of this study with previous research is difficult 
because most of the studies were conducted on younger individuals. However, in the current 
and previous studies, association between serum leptin and metabolic disorders was 
consistently independent of body adiposity. Elevated levels of serum leptin have been shown 
to be associated with insulin resistance, myocardial infarction and T2D independent of 




all-cause mortality and mortality from CVD, suggesting an optimal intermediary range of 
serum leptin for improved survival among older adults. 
The strength of this study includes the longitudinal design of Health ABC study 
and detailed assessment of life style, anthropometric, biochemical and genetic variables. Data 
were collected in several waves over a period of 10 years. Studies on hyperleptinemia, 
inflammation, adiposity and metabolic syndrome have tended to include younger individuals. 
In this study, the population was 70 years of age and older. The sampling frame for Health 
ABC study, however, includes functionally well older adults from Tennessee and 
Pennsylvania. Therefore, it is not possible to extrapolate the results from this study to the 
general population of older adults in the United States.  
 
B. Implications  
Previous studies of the prospective association of serum leptin with metabolic 
syndrome and mortality did not explore these associations in context of proinflammatory 
cytokines such as IL-6, TNF-a, CRP, and PAI-1. Proinflammatory cytokines have been 
associated with serum levels of leptin and also play a crucial role in the etiology of metabolic 
syndrome, and thus could bias the association between serum leptin and metabolic diseases. 
Therefore in the present study, it was possible to control for proinflammatory cytokines and 
body fat to provide a comprehensive picture of the association of serum leptin with metabolic 
syndrome and mortality. On average, women are more hyperleptinemic and leptin resistant 
than men. The independent association between serum leptin and metabolic syndrome among 
older women suggests that the etiology of metabolic syndrome among men and women could 
be somewhat different and may require separate approaches for preventing metabolic 




metabolic syndrome and, therefore, leptin sensitizing drugs may be helpful in ameliorating the 
components of metabolic syndrome among leptin insensitive older women. 
Although serum leptin has been shown to be positively associated with 
cardiovascular disease risk factors, our study indicates that moderately elevated leptin is 
associated with reduced risk of all-cause mortality and mortality from  CVD among older 
women. The current finding of paradoxical association of leptin with cardiovascular disease 
risk factors and mortality from CVD would help in understanding the diverse 
pathophysiological effects elicited by leptin in cardiovascular disease among older women. 
The current study suggests a need to explore the rationale behind the interaction 
between leptin receptor (I/D) genotype and percent body fat and its association with higher 
risk of diabetes as a contributing cause of mortality. Genetic variation plays an important role 
in metabolic diseases that are associated with changes in body composition. Technological 
advances for identification of single -nucleotide polymorphisms (SNPs) makes it possible to 
identify and study the role of gene polymorphisms on disease risk. If percent body fat interacts 
with leptin receptor genotype to alter the risk of death from diabetes, targeting percent body fat 
may be useful particularly in a subpopulation of older adults. 
Identification of serum leptin cut off value for the diagnosis of metabolic disorders 
may need to be studied further. Measurement of body fat mass requires expensive and invasive 
techniques, limiting its use in large population studies (88). BMI has been shown to be a good 
indicator of percent body fat (88), but a natural decrease in height among older adults may 
limit its use in this population (133). Serum leptin is relatively reliable and has been shown to 
predict body fat (88) and risk of metabolic syndrome (40 and 79). Therefore, the inclusion of 
serum leptin as a risk factor of metabolic syndrome could become an easy and feasible 
biomarker utilized at the population level, and may also have important implications in the 
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